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ABSTRACT
Adolescence is a vulnerable developmental period in regards to drug
initiation and use. The gateway hypothesis suggests that adolescent cigarette
smoking may result in a heightened risk for methamphetamine use. However,
little is understood about the role of nicotine on adolescent methamphetamine
addiction. The aim of the present study was to determine whether early, late, or
continuous adolescent nicotine exposure would alter oral methamphetamine selfadministration, extinction, or reinstatement. A total of 164 male and female
Sprague-Dawley rats were pretreated with saline or nicotine (0.16, or 0.64 mg/kg,
sc) beginning on postnatal day (PD) 25 for 10 consecutive days. On PD 35, rats
in the 0.16 and 0.64 mg/kg pretreatment groups were evenly divided and
assigned to a group that either continued to receive the same nicotine dose they
received as adolescents or saline. Rats that had received saline as adolescents
were divided into three equal groups, where they received 0.16 or 0.64 mg/kg
nicotine or continued to receive saline injections. Drug treatments starting on PD
35 continued until the end of the experiment. Thus, there were a total of 7
groups: SAL–SAL, 0.16–0.16, 0.16–SAL, SAL-0.16, 0.64–0.64, 0.64–SAL, SAL0.64. On PD 35, all rats began nose poke training. Rats were exposed to a
methamphetamine fade in, sucrose fade out procedure across 5 different
methamphetamine-sucrose combinations. This procedure resulted in exposure to
a 40 mg/l methamphetamine solution for 3 consecutive days on a FR2 schedule.
Following the last day of methamphetamine self-administration, rats were
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exposed to extinction training. Once the extinction criteria were met, rats were
given a priming injection of methamphetamine (1.0 mg/kg, ip). Data from the
present investigation revealed two main important findings: a) acquisition of oral
methamphetamine self-administration can be attained in adolescent rats; and b)
adolescent nicotine exposure differentially alters oral methamphetamine selfadministration. Exposure to a low dose of nicotine (0.16 mg/kg), but not a high
dose of nicotine (0.64 mg/kg), attenuated consumption and responding for
methamphetamine during self-administration. During the extinction and
reinstatement periods, we found that nicotine (0.16 or 0.64 mg/kg) exposure did
not alter consumption or responding for methamphetamine. Female rats showed
augmented total active nose pokes and active nose pokes within the
reinforcement period compared to male rats. Conversely, male rats showed
augmented sucrose and methamphetamine solution consumption across
methamphetamine acquisition sessions 1–6. These data suggest that for
adolescents who already present moderate cigarette smoking behavior at the
time of methamphetamine cessation treatment, total abstinence from both
nicotine and methamphetamine may be a less effective form of treatment. It may
be clinically beneficial to first treat the methamphetamine addiction, and
subsequently treat the nicotine addiction. Regardless of the method of treatment
for adolescent methamphetamine addiction, nicotine exposure should be closely
monitored.
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CHAPTER ONE
DRUG ADDICTION

Introduction
Drug addiction is a progressive, complex, and multidimensional disease
(Baler & Volkow, 2006; Everitt & Robbins, 2005; Koob & Le Moal, 1997). The
National Institute of Drug Addiction (NIDA) defines drug addiction as a “chronic,
relapsing brain disease, which is characterized by compulsive drug seeking and
use, despite harmful consequences” (NIDA, National Institute of Health [NIH], &
US Department of Health and Human Services [UDHHS], 2010). Initial voluntary
stages of drug use are typically characterized by reward and feelings of euphoria
(Everitt, 2014; Wise & Koob, 2014). However, prolonged drug use leads to a loss
of control over drug taking and can eventually result in addiction (Everitt, 2014;
Wise & Koob, 2014). A variety of potential factors influence the transition from
recreational drug use to drug addiction, including route of administration,
genetics, history of drug use, stress, and life events (Koob & Le Moal, 1997).
Drug addiction ultimately leaves addicted individuals with detrimental
physiological, psychological, behavioral, and sociocultural changes (Everitt,
2014; Everitt & Robbins, 2005; Volkow & Morales, 2015).
The stages of drug addiction are depicted in some theories as a complex,
downward spiraling model (Everitt, 2014; Koob, 2000; Koob & Le Moal, 1997).
These theories suggest that individuals who possess characteristic behavioral
traits (e.g., impulsivity, novelty-seeking, or anxiety) may be more vulnerable to
1

drug initiation (Everitt, 2014; Koob & Le Moal, 1997). These behavioral traits may
lead to acquisition of drug self-administration, wherein drug-cued learning and
drug-induced cognitive impairments occur (Everitt, 2014; Koob & Le Moal, 1997).
Consequently, continued drug use and habitual drug-taking patterns take form
via conditioned reinforcement (Everitt, 2014; Koob & Le Moal, 1997). Initially,
addictive drugs act as positive reinforcers, in which positive associations from the
drug-taking experience increase the probability of later drug-seeking behavior
(Gilpin & Koob, 2008; Wise & Koob, 2014). Continued drug use results in a
transition where the user becomes physiologically dependent on the drug (Wise
& Koob, 2014). With drug tolerance (i.e., increased reward thresholds) in place,
addictive drugs become negatively reinforcing when the probability of drug
seeking increases in order to alleviate aversive withdrawal symptoms (Gilpin &
Koob, 2008). Following binges and heavy intoxication, compulsive drug use (i.e.,
addiction) takes hold, resulting in failures in executive control (Everitt, 2014;
Koob & Le Moal, 1997). After repeated drug withdrawals, the user is likely to
experience relapse (Baler & Volkow, 2006).
Relapse is one of the major problems associated with the treatment of
drug addiction (Koob, 2013; Marchant, Li, & Shaham, 2013; Robinson &
Berridge, 2008). Drug addiction relapse rates (e.g. 40-60%) are substantial and
compare to relapse rates of other major chronic illnesses (McLellan, Lewis,
O'Brien, & Kleber, 2000). Prolonged drug use results in repeated drug-associated
pairings, such as with social, physical, or emotional contexts (McLellan et al.,
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2000). Following periods of abstinence, a drug user may encounter many of
these previously drug-paired contexts, which can generate profound
psychological reactions (McLellan et al., 2000). Thus, relapse is often driven by
the subjective desires or cravings for a drug triggered by previous drug-paired
contexts (O'Brien, 2005). In addition, relapse may result from acute re-exposure
to the drug or stress (Koob & Le Moal, 1997).
Adolescent drug use is of major concern because of the increased level of
detrimental effects associated with early drug exposure (Odgers et al., 2008). For
example, exposure to illicit drugs during adolescence is linked to sexually
transmitted diseases, teen pregnancy, low educational attainment, and crime
(Odgers et al., 2008). Further, illicit drug and alcohol exposure prior to the age of
15 is a robust indicator of substance use disorders in adulthood (Grant &
Dawson, 1997).
Cigarette smoking during adolescence is particularly problematic because
it leads to a number of adverse consequences. Of specific interest, is the
relationship between early onset of cigarette smoking and later use of illicit drugs
(Lewinsohn, Rohde, & Brown, 1999). For example, early onset of nicotine use
has been associated with early stimulant and marijuana use (Rubinstein, Rait, &
Prochaska, 2014; Weinberger & Sofuoglu, 2009). Indeed, approximately 97% of
methamphetamine users are regular users of tobacco (Brecht et al., 2004;
Brecht, Greenwell, & Anglin, 2007). Moreover, preclinical studies show that early
exposure to nicotine can increase the reinforcing effects and reduce the aversive
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effects of drugs (e.g., Neugebauer, Harrod, & Bardo, 2010; Pipkin et al., 2014).
Importantly, psychostimulant users who also smoke tobacco experience
increased stimulant dependence and health problems, as well as poorer
treatment outcomes (Weinberger & Sofuoglu, 2009).
In the current proposal, we aim to investigate the effects of nicotine
exposure on the reinforcing properties of methamphetamine in adolescent rats.
To this end, we will assess adolescent nicotine exposure on acquisition of
methamphetamine oral self-administration, extinction, and reinstatement. The
following chapters discuss the importance of the adolescent period, relevant
neurotransmitter systems, nicotine, methamphetamine, self-administration
paradigm, and the rationale for the proposed study.

4

CHAPTER TWO
ADOLESCENCE

Introduction
Adolescence is a pivotal transitional period during development that
bridges the gap between childhood and adulthood. The adolescent period is
typically regarded as roughly 10 to 19 years of age and characterized by many
different hormonal, physical, psychological, and social changes (Sacks, 2003).
Specifically, early adolescence (i.e., ~10-14 years) is characterized by the onset
of physical (e.g., onset of puberty), cognitive (e.g., abstract thought), social (e.g.,
sense of identity), and emotional (e.g., mood swings) development (Blakemore,
2012; Dumontheil, 2014; Marcia, 1980; Sawyer et al., 2012; Zeman, Cassano,
Perry-Parrish, & Stegall, 2006). In late adolescence (i.e., ~15-19 years), physical
changes begin to subside, while the ability for abstract thought, cognitive control,
drive for independence, and emotional regulation continues to develop
(Blakemore, 2012; Dumontheil, 2014; Marcia, 1980; Sawyer et al., 2012; Zeman
et al., 2006).
The complex changes experienced during adolescence promote
increased risk-taking behavior (e.g., substance use, unsafe sex, illegal activities,
and dangerous driving) (Bond, Carlin, Thomas, & Patton, 2001; Herrenkohl et al.,
2000). Social development in adolescents is characterized by a need for
independence, in which less time is spent with parents or family and more time is
spent with peer groups (Gorrese & Ruggieri, 2012). Increases in peer-influence
5

may potentially lead to risky behavior, such as substance use (Berndt, 1979;
Spear, 2000). Risk-taking behavior may also result from the positive association
with the novelty, complexity, or intensity of a new experience, which often is the
reason for adolescent drug initiation (Arnett, 1992).
Throughout adolescence there are many changes in the development of
brain areas that responsible for response inhibition, risk, reward, and emotion
(Steinberg, 2005). Specifically, subcortical areas (e.g., ventral striatum, nucleus
accumbens, hippocampus, and amygdala) involved in emotion, motivation, and
reward, develop in early adolescence (Crews, He, & Hodge, 2007; Wetherill &
Tapert, 2012). Cortical brain areas such as the prefrontal cortex, which is
important in executive functioning (e.g., inhibitory control), do not finalize
connections until early adulthood, suggesting that adolescents may lack impulse
control and effective decision-making processes, while maintaining increases in
motivation, emotion, and reward sensitivity (Casey & Jones, 2010; Luciana,
2013; Steinberg, 2010; Wetherill & Tapert, 2012). Given the weak top-down
cognitive control and heightened emotional reactivity evident during normal
adolescent brain development, adolescents are susceptible to difficulties with
affect, risk-taking, inhibitory control, and reward-related behaviors, all of which
play a role in substance initiation and use (Casey & Jones, 2010).
Depending on the brain area and period of development, many neurons in
the brain undergo synaptic pruning, in which the number of neural connections
are reduced (Giedd et al., 1999; Gogtay et al., 2004). This synaptic pruning leads
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to decreased cortical volume and thickness (Giedd et al., 1999; Gogtay et al.,
2004). For example, during adolescence, pruning takes place in the amygdala,
nucleus accumbens, and prefrontal cortex (Andersen, Thompson, Rutstein,
Hostetter, & Teicher, 2000; Teicher, Andersen, & Hostetter, 1995; Zehr, Todd,
Schulz, McCarthy, & Sisk, 2006). Although this pruning process is not entirely
understood, the neuronal remodeling that occurs during adolescence maybe an
essential stage to facilitate developmental plasticity that helps prepare for more
mature behavior in adulthood (Crews et al., 2007). However, this period of
neuronal change results in adolescents being more vulnerable to alterations in
the neuronal environment brought about by psychopharmacological agents
(Geier, 2013).

Adolescence and Drug Addiction
Adolescence is a period of increased illicit drug initiation because
adolescents often display impulsivity in decision-making (Kalivas & Volkow,
2005). Many adult smokers begin smoking within their teenage years, which
often leads to health complications (UDHHS, 2012). Based on a self-report
measure of adults with substance use disorders, the median age for illicit drug
initiation was 16, and initiation after age 20 was rare (Good & Radcliffe, 2011).
Cessation of smoking is more difficult for individuals who begin smoking at an
earlier age when compared to those who initiate smoking later in life (Stanton &
Grimshaw, 2013). Additionally, nicotine addiction in adolescence develops
rapidly, creating difficulty for smoking cessation in this age group (DiFranza &
7

Richmond, 2008). The use of nicotine in adolescence produces a more sensitive
response to the positive rewarding and reinforcing effects of nicotine (Torres,
Tejeda, Natividad, & O’Dell, 2008; Kota, Martin, Robinson, & Damaj, 2007).
Similar to nicotine, methamphetamine is a highly addictive psychoactive
drug that poses enormous problems for society (Panenka et al., 2013). Due to
the relatively easy synthesis and production, as well as the highly addictive
nature of methamphetamine, the drug has become one of the most widely used
and distributed psychostimulants in the world (United Nations Office on Drugs
and Crime [UNODC], 2010). In a 2010 Monitoring the Future study, it was found
that adolescent methamphetamine use among high school students was 1.6%
(Panenka et al., 2013). Although methamphetamine use in adolescence declined
in 2010, the prevalence rates for methamphetamine use have fluctuated
substantially throughout past decades (Johnston, O’Malley, Bachman, &
Schulenberg, 2012). Evidence from animal models suggest that adolescents may
be more vulnerable to the effects of methamphetamine and other drugs of abuse,
because they are less sensitive to withdrawal and can develop robust drug
sensitization when drug use initiates in early to mid-adolescence (SchrammSapyta, Walker, Caster, Levin, Kuhn, 2009).
Given the many neurological changes during adolescence, the effects of
psychostimulants like nicotine and methamphetamine on the vulnerable
adolescent brain need to be considered in more detail. In order to study the
effects of these addictive psychostimulants on the adolescent brain and resulting
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behavior, it is imperative to understand changes in relevant neurotransmitter
systems across the period of adolescence. Therefore, the following two chapters
will give an overview of the cholinergic and monoamine neurotransmitter
systems.
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CHAPTER THREE
ACETYLCHOLINE

Introduction
Acetylcholine (ACh) was the first neurotransmitter to be identified and is
found in both the central and peripheral nervous systems (Sofuoglu & Mooney,
2009; Stjärne, 1999). Peripheral action of ACh at the neuromuscular junction is
vital for skeletal and cardiac muscle contraction (Brown, Wetzel, & Dunlap, 1982;
Fambrough, 1979). Within the central nervous system (CNS), ACh is involved in
numerous psychological processes, including addiction, attention, arousal,
motivation, mood, reward, learning, memory, and stress (Acquas, Wilson, &
Fibiger, 1996; Mansvelder & McGehee, 2002; Pepeu & Blandina, 1998;
Poorthuis & Mansvelder, 2013; Robbins, 1997; Thiel, Huston, & Schwarting,
1998; Warner-Schmidt et al., 2012). Neurological and psychiatric disorders that
are due to cholinergic dysfunction include, Parkinson’s, Alzheimer’s, bipolar
disorder, schizophrenia, and substance use disorders (Lester, Rogers, & Blaha,
2010; Levin, 2012; Maskos, 2008; McEvoy & Allen, 2002).

Acetylcholine Synthesis, Release, and Catabolism
The synthesis of ACh is initiated in the presynaptic terminals of cholinergic
neurons. Within these cholinergic neurons, ACh is formed from the two
compounds choline and acetyl-CoA in the presence of the enzyme choline
acetyltransferase (ChaT) (Parsons, Prior, & Marshall, 1993; Prado et al., 2002;
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Scremin & Jenden 1993). In addition to producing ACh, ChaT levels are often
used as a marker to determine if a neuron is cholinergic (Kimura, McGeer, Peng,
& McGeer, 1980). Intracellular choline concentrations are determined by the
uptake of choline into the presynaptic axon terminal by the high-affinity choline
transporter (CHT1) (Bellier & Kimura, 2011; Simon, Atweh, & Kuhar, 1976). In
the process of ACh synthesis, choline serves as the rate-limiting step (Bellier &
Kimura, 2011; Simon et al., 1976). After formation, ACh is then accumulated in
synaptic vesicles by the actions of the vesicular acetylcholine transporter
(VAChT) (Parsons et al., 1993; Prado et al., 2002; Scremin & Jenden, 1993).
In response to an action potential reaching the axon terminal, an influx of
extracellular calcium (Ca2+) enters the neuron through voltage-gated Ca2+
channels. ACh containing vesicles then bind to the cytosolic neuronal membrane,
allowing for the subsequent release of ACh into the synaptic cleft (Dunant &
Israel, 2000; Langley & Grant, 1997; Lima, Prado, Prado, & Kushmerick, 2010).
The action of ACh containing vesicles fusing to the neuronal membrane is
promoted by the binding of vesicle soluble N-ethylmaleimide-sensitive-factor
attachment-protein receptor, or v-SNARE to a corresponding target SNARE (tSNARE) on the active zone of the cytoplasmic membrane (Dunant & Israel,
2000; Israel & Dunant, 1998).
The release of ACh by the presynaptic neuron into the synaptic cleft
results in diffusion of ACh to the post-synaptic neuron, where ACh either binds to
cholinergic receptors and/or is subjected to enzymatic degradation by
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acetylcholinesterase (AChE) into choline and acetic acid (Prado, Roy, Kolisnyk,
Gros, & Prado, 2013; Silman & Sussman, 2005). The choline is then recycled
back into the terminal of the presynaptic neuron by uptake, predominately carried
out by CHT1 (Matsuo et al., 2011).

Acetylcholine Receptors and Subtypes
ACh receptors are divided into two major classes: muscarinic (mAChRs)
and nicotinic (nAChRs) receptors (Picciotto, Higley, & Mineur, 2012). The
receptors were named based on the drugs that bound to them. Specifically, the
stimulant nicotine binds to nAChRs, whereas the psychoactive ingredient in
certain mushrooms, muscarine, binds to mAChRs (Haga, 2013; Papke, 2014).
The mAChRs are metabotropic receptors, which promote the initiation of second
messenger systems and indirectly open ion channels on the post-synaptic
neuron (Wess, 2003). The five subtypes of mAChRs (i.e., M1-5) are all classified
as G-protein-coupled receptors, of which the M1, M3, and M5 type belong to the
Gq family, whereas M2 and M4 belong to the Gi/o family (Caulfield & Birdsall,
1998; Haga, 2013; Picciotto et al., 2012; Wess, 1996). The action of mAChRs is
initiated when ACh binds to the metabotropic receptor that is attached to
intercellular G-proteins (Ishii & Kurachi, 2006). Following this initial binding,
mAChRs belonging to the Gq family (i.e., M1, M3, and M5) begin an information
cascade (Haga, 2013; Ishii & Kurachi, 2006). This signaling pathway starts with
the activation of phospholipase C (PLC), which initiates the phosphatidylinositol
4,5-bisphosphate (PIP2) cascade by hydrolyzing PIP2 into diacylglycerol (DAG)
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and inositol 1,4,5-triphosphate (IP3). Intracellular Ca2+ is mobilized by IP3 and
protein kinase C (PKC) is activated by DAG and Ca2+ (Berridge, & Irvine, 1984;
Haga, 2013; Ishii & Kurachi, 2006). The second messenger signaling of mAChRs
belonging to the Gi/o family (i.e., M2 and M4) differs from receptors of the Gq
family, in that they inhibit adenylyl cyclase from converting ATP into cyclic AMP,
which decreases cAMP production and protein kinase A activity (Haga, 2013;
Ishii & Kurachi, 2006; Nathanson, 2000; Onali & Olianas, 1995; Wess, 1996). In
addition to decreasing cAMP, mAChRs of the Gi/o type also act on G proteincoupled potassium (K+) channels, which allows for the efflux of K+ and the
hyperpolarization of the neuronal membrane, ultimately inhibiting action
potentials (Haga, 2013; Ishii & Kurachi, 2006).
In contrast to mAChRs, nAChRs function as ionotropic receptors that act
as non-selective cation channels (Picciotto, Caldarone, King, & Zachariou, 2000).
The 11 different neuronal nAChR subtypes are homomeric or heteromeric and
are composed of five different  or  subunits (Picciotto et al., 2000; Picciotto et
al., 2012). After the direct binding of ACh to the two  or  subunits, the nAChRs
open and allow for the influx of Ca2+ and sodium (Na+) into the cytoplasm,
leading to the depolarization of the post-synaptic neuron (Beker, Weber, Fink, &
Adams, 2003; Picciotto et al., 2000). nAChRs are dispersed along the postsynaptic terminal and are also found on the presynaptic terminal, whereas
nAChRs at the neuromuscular junction are found directly opposite from ACh
release sites, thus facilitating rapid muscle movement (McGehee, Heath, Gelbert,
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Devay, & Role, 1995; Pires-Oliveira, Moen, & Akaaboune, 2013; Vidal &
Changeux, 1993).

Acetylcholine Innervation
There is extensive cholinergic innervation because of the essential action
of ACh at synapses in both the CNS and at the neuromuscular junction of the
peripheral nervous system (PNS) (Picciotto et al., 2012; Pires-Oliveira et al.,
2013; Ren et al., 2011; Zaborszky et al., 2008). Within the CNS, cholinergic
neurons are found in various brain nuclei, including the pedunculopontine and
laterodorsal tegmental areas, the medial habenula, and the basal forebrain
complex, with widespread projections all over the brain (Picciotto et al., 2012).
The widespread effects of ACh on behavior are largely due to the diffuse nature
of the cholinergic system. Interestingly, ACh can function as a neuromodulator in
the mesolimbic dopamine (DA) system, which is important for reward and
addiction (Fagen, Mansvelder, Keath, & McGehee, 2003); Mansvelder, De
Rover, McGehee, & Brussaard, 2003).

Nicotinic Acetylcholine Receptor Development
Due to the large number of adolescents who smoke cigarettes (World
Health Organization [WHO], 2001), it is important to examine the development of
nicotinic acetylcholine receptors (nAChRs). The expression and functional
properties of nAChRs often vary across childhood, adolescence, and adulthood
(Slotkin, 2002), which the expression of some nAChR subunits (e.g., 2 and 3 in
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the thalamus; 4 in the cortex, thalamus, and brainstem; 7 in the thalamus and
brainstem; 2 in most brain areas besides the striatum) are constant across
development (Zhang, Liu, Miao, Gong, & Nordberg, 1998). The widely dispersed
nAChR 42 that is involved in learning processes, is expressed more in early
adolescence than adulthood within 33 different brain areas (Doura, Gold, Keller,
& Perry, 2008). Another nAChR involved in long-term memory, 7 is also
expressed more in early adolescence than adulthood within 12 different brain
regions (Doura et al., 2008). DA release via nAChR stimulation in midbrain (i.e.,
ventral striatal) DA neurons is heightened during adolescence when compared to
adulthood (Azam, Chen, & Leslie, 2007). The latter finding is important because,
the addictive and reinforcing properties of nicotine involves ventral striatal DA
release (Corrigall, Franklin, Coen, & Clarke, 1992; Imperato, Mulas, & Di Chiara,
1986; Nisell, Nomikos, & Svensson, 1995).
Therefore, many changes in the cholinergic system relating to nAChRs
are evident in early postnatal development, which some receptor changes occur
during the adolescent period (Dwyer, McQuown, & Leslie, 2009). Pivotal changes
in the development of the adolescent cholinergic system may leave this system
vulnerable to pharmacological insult via certain drugs of abuse (i.e., nicotine).
Thus, early postnatal and adolescent nicotine exposure may alter brain structure
and function later on in life (Dwyer et al., 2009).

15

CHAPTER FOUR
MONOAMINE NEUROTRANSMITTERS

Introduction
Monoamine neurotransmitters are characterized as containing one amino
group attached to an aromatic ring via a two-carbon chain. Specifically,
catecholamine neurotransmitters are a type of monoamine neurotransmitter that
contain a catechol and side chain amine (Fernstrorn & Fernstrom, 2007). There
are three different catecholamine neurotransmitters that are derived from the
amino acid tyrosine: dopamine (DA), norepinephrine (NE), and epinephrine
(Fernstrorn & Fernstrom, 2007). An important indolamine synthesized from
tryptophan is the neurotransmitter serotonin (5-HT) (Fidalgo, Ivanov, & Wood,
2012). Due to the relevance of these neurotransmitter systems to the present
study, the catecholamine neurotransmitters DA and NE, as well as the
indolamine 5-HT, will be discussed in the following sections.

Dopamine
The dopaminergic system is known to mediate a number of behaviors,
including motivation, sleep and wake cycle, learning, mood, cognition,
movement, addiction, and reward (Alcaro, Huber, & Panksepp, 2007; Dzirasaet
al., 2006; Gorwood et al., 2012; Plowman & Kleim, 2011; Salamone & Correa,
2012; Schultz, 2010; Yacubian & Buechel, 2009). Psychological and neurological
diseases or disorders stemming from dopaminergic dysfunction include
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Parkinson’s, schizophrenia, Tourette’s syndrome, anxiety, depression, attentiondeficit hyperactivity disorder (ADHD), and substance use disorders (Bisaglia,
Greggio, Beltramini, & Bubacco, 2013; Buse, Schoenefeld, Münchau, &
Roessner, 2013; de la Mora, Gallegos-Cari, Arizmendi-García, Marcellino, &
Fuxe, 2010; del Campo, Chamberlain, Sahakian, & Robbins, 2011; El Mansari et
al., 2010; Grace, 2010; Schmitt & Reith, 2010).

Dopamine Synthesis, Release, and Catabolism
The synthesis of DA begins in the terminal of the presynaptic neuron,
where the amino acid tyrosine is converted into L-dihydroxyphenylalanine (LDOPA) in the presence of tyrosine hydroxylase (Elsworth & Roth, 1997; Feve,
2012; Haavik & Toska, 1998; Icard-Liepkalns et al., 1993). L-DOPA is then
converted into DA in the presence of aromatic amino acid decarboxylase (DOPA
decarboxylase) (Bertoldi, 2014; Elsworth & Roth, 1997; Feve, 2012). Tyrosine
hydroxylase is the rate-limiting step in the process of DA synthesis and
production (Elsworth & Roth, 1997; Haavik & Toska, 1998). Vesicular
monoamine transporters (VMAT), which are found at both dendrites and the axon
terminals of dopaminergic neurons, store DA in synaptic vesicles (Elsworth &
Roth, 1997; Henry et al., 1994; Pifl et al., 2014).
Similar to ACh release, the release of DA and other classical monoamine
neurotransmitters (e.g., NE and 5-HT) occurs through Ca2+−dependent
exocytosis into the synaptic cleft (Jaffe, 1998; Sofuoglu & Sewell, 2009; Suedhof,
2012). Following release from the presynaptic terminal, DA either diffuses into
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the synaptic cleft to bind with DA receptors on the presynaptic or post-synaptic
terminal, or undergoes reuptake into the presynaptic terminal by DA transporters
(DAT) (Elsworth & Roth, 1997).
The process of reuptake by DAT is critical in maintaining consistent intraand extracellular DA levels through the recycling of DA (Elsworth & Roth, 1997;
Schmitt, Rothman, & Reith, 2013; Vaughan & Foster, 2013). DAT also serves as
a marker to distinguish dopaminergic neurons through use of ligands and
antibodies. DAT functions as the site of action for some psychostimulants, such
as methamphetamine (Elsworth & Roth, 1997; Schmitt et al., 2013; Vaughan &
Foster, 2013). Once DA is transported into the presynaptic neuron, it is either
repackaged into vesicles for reuse or is enzymatically degraded into a number of
different metabolites (Elsworth & Roth, 1997). Catabolism of DA depends on the
cell type, brain region, and species (Elsworth & Roth, 1997). In the striatum,
monoamine oxidase (MAO) located on the outer membrane of mitochondria is
the enzyme that converts DA into 3,4-dihydroxyphenylacetic acid (DOPAC),
which is then converted into homovanillic acid (HVA) by the enzyme catechol Omethyltransferase (COMT) located in the cytoplasm (Elsworth & Roth, 1997;
Goldstein & Lieberman, 1992; Napolitano, Cesura, & Da Prada, 1995). In
rodents, the main end product of DA degradation is DOPAC, whereas HVA is the
main DA metabolite in humans (Elsworth & Roth, 1997).
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Dopamine Receptors and Subtypes
There are five subtypes of dopamine receptors (i.e., D1-D5), all of which
are heterotrimeric G protein-coupled receptors (Ares-Santos, Granado, &
Moratalla, 2013; Beaulieu & Gainetdinov, 2011; Elsworth & Roth, 1997). There
are two major families of DA receptors, with D1 and D5 receptors belonging to the
D1-like family, and D2, D3, and D4 receptors belonging to the D2-like family (AresSantos et al., 2013; Beaulieu & Gainetdinov, 2011; Elsworth & Roth, 1997).
When DA binds to receptors of the D1-like family on the post-synaptic
membrane, it causes the Gs/olf proteins to activate adenylyl cyclase, which then
activates the second messenger molecule cAMP that increases the enzyme
PKA. Increases in PKA leads to the phosphorylation of neuronal proteins,
regulation of ion channel functioning, and depolarization of the post-synaptic
neuron (Ares-Santos et al., 2013; Beaulieu & Gainetdinov, 2011; Vallone, Picetti,
& Borrelli, 2000).
When DA binds to receptors of the D2-like family on either the pre- or postsynaptic membrane, it causes the Gi/o proteins to inhibit activation of adenylyl
cyclase. Inhibition of adenylyl cyclase leads to the inhibition of cAMP and PKA
activity, inducing hyperpolarization of the receptor bound neuron (Ares-Santos et
al., 2013; Beaulieu & Gainetdinov, 2011; Missale et al., 1998; Vallone et al.,
2000). D1 and D2 receptor subtypes are diffuse within the brain and exist in all
known dopaminergic projections, with high concentrations in the striatum,
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nucleus accumbens, olfactory bulb, amygdala, frontal cortex, substantia nigra,
and at lower levels in the hippocampus and ventral tegmental area (Ares-Santos
et al., 2013; Beaulieu & Gainetdinov, 2011; Gangarossa et al., 2012).

Dopamine Innervation
The primary production of DA occurs in the neurons of the substantia
nigra and ventral tegmental area (Baik, 2013). The neuronal projections from
these brain areas make up three major dopaminergic pathways: mesolimbic,
mesocortical, and nigrostriatal (Maharajan, Maharajan, Ravagnan, & Paino,
2001). The nigrostriatal pathway consists of dopaminergic neurons projecting
from the substantia nigra to the striatum (Dahlstrom & Fuxe, 1964; Janhunen &
Ahtee, 2007). The mesocortical pathway consists of dopaminergic neurons
projecting from the ventral tegmental area to the frontal cortex (Sogabe,
Yagasaki, Onozawa, & Kawakami, 2013). The mesolimbic pathway is comprised
of dopaminergic neurons from the ventral tegmental area projecting to the
nucleus accumbens (Ikemoto, 2007; Koob, 1992; Wise, 1996). The mesolimbic
pathway, involved in the regulation of reward, motivation, and emotion, is subject
to physiological changes following repeated exposure to addictive substances
(Baik, 2013; Nestler & Carlezon, 2006). The changes to the mesolimbic system
produced by certain addictive drugs are thought to be responsible for drug
dependence (Thomas, Kalivas, & Shaham, 2008).
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Dopaminergic System Development
Development of the dopaminergic system is important to examine
because stimulants like methamphetamine bind to vesicular DA transporters,
causing the release of DA into the synaptic cleft (Courtney & Ray, 2014). The
expression of DA receptor subtypes varies across developmental periods (Spear,
2010). At birth, D1 and D2 receptors are present in the striatum, but by PD 15 D1
receptors begin to increase in density (Gelbard, Teicher, Faedda, & Baldessarini,
1989). By adulthood, there is a three-fold increase in D1 receptors, compared to
D2 receptors in the striatum (Gelbard et al., 1989). D1 receptor expression peaks
in the striatum around PD 40 and then stabilizes to adult levels around PD 60
(Gelbard et al., 1989; Teicher et al., 1995). This increase in D1 receptor
expression may be important for the early development of the basal ganglia
(Meng, Ozawa, Itoh, & Takashima, 1999).
D2 receptors also increase in density across early development and
adolescence, peaking around PD 21-28, followed by a reduction in receptor
density going into adulthood (Demotes-Mainard, Henry, Jeantet, Arsaut, &
Arnauld, 1996; Murrin & Zeng, 1986; Tarazi, Tomasini, & Baldessarini, 1998).
Within the striatum, D2 receptors develop at the same rate, but with less density
than D1 receptors (Andersen et al., 2000; Teicher et al., 1995). Within the limbic
system, D3 receptor expression is observed as early as PD3 and increases in
receptor density occur through adulthood (Demotes-Mainard et al., 1996; Fallon,
Riley, Sipe, & Moore, 1978). Further, DAT levels are increased during
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adolescence when compared to adulthood (Meng et al., 1999). Innervation of DA
neurons from the striatum and midbrain to the prefrontal cortex peaks during
adolescence (Benes, Taylor & Cunningham, 2000). Thus, alterations in the
dopaminergic system may cause adolescents to express heightened reward
sensitivity compared to adults, which leaves this group particularly vulnerable to
substance use (Geier, 2013).

Norepinephrine
Within the CNS, NE is involved in a variety of behavioral outcomes,
including attention, arousal, cognition, impulsivity, memory, emotion, stress, drug
seeking, and reward (Flavin & Winder, 2013; Goddard et al., 2010; Hamon &
Blier, 2013; Howells, Stein, & Russell, 2012; Logue & Gould, 2014; Pattij &
Vanderschuren, 2008; Sofuoglu & Sewell, 2009; Tully & Bolshakov, 2010).
Dysfunction of the noradrenergic system results in various disorders and
diseases, ranging from ADHD, major depressive disorder, anxiety disorders,
bipolar disorder, to addiction and substance use disorders (Belujon & Grace,
2011; El Mansari et al., 2010; Fitzgerald, 2013; Goddard et al., 2010; Park,
Caballero, & Omidian, 2014; Pervanidou, 2008; Sofuoglu & Sewell, 2009; Swan,
2010).

Norepinephrine Synthesis, Release, and Catabolism
NE is synthesized from DA in the presence of dopamine-β-hydroxylase
(Ressler & Nemeroff, 1999; Sofuoglu & Sewell, 2009). The synthesis of NE can
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occur in either DA containing vesicles or NE is transferred from the cytoplasm
into synaptic vesicles by VMAT and is stored in the axon terminal (Ressler &
Nemeroff, 1999; Sofuoglu & Sewell, 2009).
Following Ca2+−dependent exocytosis, NE undergoes reuptake by the NE
transporter (NET) and is reused, or MAO enzymatically destroys NE (Bönisch, &
Brüss, 2006; Ressler & Nemeroff, 1999; Sofuoglu & Sewell, 2009). MAO
converts NE into aldehyde, which is then converted into either 3,4dihydroxyphenylglycol (DHPG) or 3,4-dihydroxymandelic acid (DHMA) by
dehydrogenase or reductase enzymes (Ressler & Nemeroff, 1999). COMT
continues to catabolize these compounds, especially when NE levels are high
(Huotari et al., 2002; Ressler & Nemeroff, 1999).

Norepinephrine Receptors and Subtypes
Noradrenergic receptors can be activated by both NE and epinephrine,
and are G protein-coupled receptors that exist in two major family types,  or 
receptors (Bylund et al., 1994). The  receptors are divided into 1 and 2
adrenergic families (Bylund et al., 1994). The 1 receptor family is divided into
1A, 1B, and 1D subtypes, whereas the 2 adrenergic family is divided into 2A,
2B, and 2C subtypes (Bylund et al., 1994; Oh et al., 2013; Segura et al, 2010).
The 1 family is mostly comprised of post-synaptic excitatory Gq protein coupled
receptors, which activates PLC (Sofuoglu & Sewell, 2009). The 2
adrenoreceptors are located on pre- and post-synaptic terminals and are coupled
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to the Gi/o protein, which inhibits adenylyl cyclase (Sofuoglu & Sewell, 2009). The
inhibition of adenylyl cyclase results in a reduction of cAMP production, causing
hyperpolarization of the neuronal membrane and reduced neuronal firing
(Stojilkovic, 2012).
The  adrenoreceptors are divided into 1, 2, and 3 subtypes and are
coupled to the Gs protein, which activates adenylyl cyclase (Sofuoglu & Sewell,
2009). Activation of adenylyl cyclase results in the conversion of ATP into cAMP,
leading to changes in ion channels and subsequent depolarization of the
neuronal membrane (Stojilkovic, 2012).

Norepinephrine Innervation
Noradrenergic nuclei are primarily found in the locus coeruleus of the
brain stem and project to nearly every area of the brain (Szabadi, 2013). In
comparison to the dopaminergic system, the DA projections from the ventral
tegmental area and substantia nigra are relatively limited when compared to NE
neuronal projections extending from the locus coeruleus (Ressler & Nemeroff,
1999).

Noradrenergic System Development
Like other neurotransmitter systems, the NE system experiences changes
in NE release and receptor expression throughout development. For example,
social stress occurring during early adolescence (i.e., PD 28), but not midadolescence (i.e., PD 42) produces heightened spontaneous locus coeruleus
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discharge, and attenuates responsiveness to sensory stimuli (Bingham et al.,
2011). Cerebral -adrenoreceptor expression rapidly increases between PD 10
and PD 21, after which receptor expression remains fairly constant up to midadolescence (i.e., PD 42), but then quickly attenuates thereafter (Pittman,
Minneman, & Molinoff, 1980). In contrast, cerebellar -adrenoreceptor
expression rises slowly from PD 5 to PD 42, where receptor levels are constant
up to at least 6 months of age (Pittman et al., 1980). Due to the remodeling that
the noradrenergic system undergoes during development and adolescence, in
particular, it is possible that adolescent stimulant exposure produces
fundamental changes in the NE system during this vulnerable time period
(Trauth, Seidler, Ali, & Slotkin, 2001). Adolescent stimulant exposure to nicotine
or methamphetamine may fundamentally alter noradrenergic and dopaminergic
systems, potentially resulting in heightened reward sensitivity and susceptibility
to drug abuse (Trauth et al., 2001).

Serotonin
5-HT is a monoamine found in both the PNS and CNS (Fidalgo et al.,
2012). In the PNS, roughly 95% of the 5-HT is produced within enterochromaffin
cells of the digestive tract (Gershon, 2004). In the CNS, 5-HT is readily produced
from neurons originating in the raphe nuclei of the brain stem (Adell, Celada,
Abellán, & Artigas, 2002). 5-HT is involved in a wide variety of
neuropsychological processes, including cognition, decision-making, learning,
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memory, appetite, sleep, sexual desire, social behavior, mood, and emotion
(Cowen & Sherwood, 2013; Homberg, 2012; Lam, Garfield, Marston, Shaw, &
Heisler, 2010; Kiser, Steemers, Branchi, & Homberg, 2012; Menese & Liy-

Salmeron, 2012; Montgomery, Baldwin, & Riley, 2002; Monti, 2011). Dysfunction
of the serotonergic system is related to a number of disorders, such as
Parkinson’s disease, Alzheimer’s disease, schizophrenia, depression, anxiety,
phobias, panic attacks, post-traumatic stress disorder, antisocial behavior, drug
abuse, addiction, and substance use (Eggers, 2013; Fernandez & Gaspar, 2012;
Huot & Fox, 2013; Kirby, Zeeb, & Winstanley, 2011; Meltzer, 1989; Nordquist, &
Oreland, 2010; Rodríguez, Noristani, & Verkhratsky, 2012).

Serotonin Synthesis, Release, and Catabolism
The synthesis of 5-HT can occur in either the soma or axon terminal of
serotonergic neurons (Daszuta, Hery, & Faudon, 1984; Daszuta, Faudon, &
Hery, 1984). 5-HT is derived from tryptophan, which is obtained from the diet
(Leathwood, 1987). Tryptophan is converted into 5-hydroxy-l-tryptophan (5-HTP)
by the enzyme l-tryptophan-5-monooxygenase hydroxylase (tryptophan
hydroxylase), which serves as the rate-limiting step in the biosynthesis of
serotonin (Boadle-Biber, 1993; Fidalgo, et al., 2012; Leathwood, 1987; Tyce,
1990). 5-HTP is then converted into 5-HT by the enzyme aromatic-l-amino-acid
decarboxylase (DOPA decarboxylase) (Boadle-Biber, 1993; Fidalgo, et al., 2012;
Leathwood, 1987; Tyce, 1990). Newly formed 5-HT is then packaged into
secretory synaptic vesicles for protection against degradation by MAO and to
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await release into the synaptic cleft via Ca2+−dependent exocytosis (Jorgensen,
Christensen, & Gether, 2014; Tamir, & Gershon, 1990).
Following release into the synaptic cleft, 5-HT either binds to pre- or postsynaptic 5-HT receptors and/or is removed from the synaptic cleft by the 5-HT
transporter (SERT) through active reuptake into the presynaptic terminal (Fuller,
1986; Ni & Watts, 2006; Südhof, 2008). After reuptake, 5-HT is either
repackaged or undergoes enzymatic degradation (Duncan, Johnson, & XiaoMing, 2012). The removal of 5-HT from the synaptic cleft is essential to avoid
potentially deadly levels of extracellular 5-HT (i.e., serotonin syndrome) (Squires,
Talbot, Rubakhin, & Sweedler, 2007). 5-HT catabolism within the CNS begins
when MAO converts 5-HT into 5-hydroxy-3-indole acetaldehyde (5-HAIL), which
is further broken down into 5-hydroxy-3-indoleacetic acid (5-HIAA) by aldehyde
dehydrogenase (Squires et al., 2006).

Serotonin Receptors and Subtypes
5-HT receptors are classified into seven major types: 5-HT1, 5-HT2, 5-HT3,
5-HT4, 5-HT5, 5-HT6, and 5-HT7 (Berger, Gray, & Roth, 2009; Hoyer, Hannon, &
Martin, 2002). All seven types, with the exception of the 5-HT3 ligand-gated ion
channel, are G-protein-coupled receptors (Hoyer et al., 1994; Nichols & Nichols,
2008). Specifically, the 5-HT1 family (i.e., 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5HT1F, 5-HT5A, and 5-HT5B) are Gi/o coupled receptors that, when activated, cause
the inhibition of adenylyl cyclase and decrease the production of cAMP (Hamel,
1999; Hartig, Branchek, & Weinshank, 1992; Kobilka et al., 1987; Lovenberg et
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al., 1993; Noda, Higashida, Aoki, & Wada, 2004; Wacker et al., 2013; Watts &
Neve, 2005; Wisden et al., 1993). The 5-HT2 family (i.e., 5-HT2A, 5-HT2B, and 5HT2C) are Gq/11 coupled receptors that cause the hydrolysis of membrane
phosphoinositides into DAG and inositol phosphates (Belmer et al., 2014;
Chambers & Nichols, 2002; Facchinetti, & Russo de Boland, 2001; HuidobroToro, Valenzuela, & Harris, 1996). DAG and inositol phosphates then work as
signaling molecules that ultimately lead to PKC activation or elevation of
intracellular calcium, respectively (Nichols & Nichols, 2008). The 5-HT4, 5-HT6,
and 5-HT7 families are Gs coupled receptors that, when bound to lead to adenylyl
cyclase activation, result in the conversion of ATP into cAMP (Hamblin, Guthrie,
Kohen, & Heidmann, 1998; Kang et al., 2005; Nedi, White, Coupar, & Irving,
2011). The 5-HT3 receptor is a ligand-gated ion channel composed of five
subtypes (i.e., 5-HT3A, 5-HT3B, 5-HT3C, 5-HT3D, and 5-HT3E) (Massoura, Dover,
Newman, & Barnes, 2011; Takimoto et al., 2014). When 5-HT binds to the 5-HT3
receptor, an excitatory post-synaptic potential occurs on the neuronal membrane
(Barnes, Hales, Lummis, & Peters, 2009; Connolly & Wafford, 2004).

Serotonin Innervation
The brain is innervated by serotonergic neurons that primarily arise from
raphe nuclei of the brain stem, and a smaller amount of neurons from the lateral
reticular formation (Hornung, 2003). Serotonergic neurons extending from the
raphe nuclei can be divided into a rostral group, which projects to areas of the
mesencephalon, rostral pons, and forebrain, and a caudal group, which projects
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to the caudal pons, caudal medulla oblongata, brain stem, and spinal cord
(Hornung, 2003; Moore, Halaris, & Jones, 1978). The rostral projections account
for 85% of 5-HT within the brain, most of which project to the ventral tegmental
area and interpeduncular nucleus (Halliday & Tork, 1986; Hornung, 2003).

Serotonergic System Development
In the rodent brain, 5-HT levels peak in early development (i.e., PD 21-30)
and gradually decline to adult levels (Hedner, Lundell, Breese, Mueller, &
Hedner, 1986; Murrin, Sanders, & Bylund, 2007; Toth & Fekete, 1985). The
number of 5-HT synapses within the basal forebrain increases from birth to PD
14, followed by a rapid decline during early adolescence (Dinopoulos, Dori, &
Parnavelas, 1997; Dori, Dinopoulos, & Parnavelas, 1998). 5-HT receptor
subtypes are also expressed in different time periods and brain regions, with
peaks either at birth or just before adolescence (Bar-Peled et al., 1991; Morilak &
Ciaranello, 1993; Vizuete et al., 1997). For example, cortical 5-HT2A receptors
(Morilak & Ciaranello, 1993), as well as striatal and hippocampal 5-HT7 receptors
(Vizuete et al., 1997) are in greatest numbers immediately before adolescence
and steadily decline to adult levels, whereas 5-HT1A receptors reach peak
expression at birth, but rapidly decline across adolescence and into adulthood
(Bar-Peled et al., 1991; Burnet, Eastwood, & Harrison, 1994; Daval, Vergé,
Basbaum, Bourgoin, & Hamon, 1987). 5-HT turnover in the nucleus accumbens
also shows ontogenetic differences, as 5-HT turnover is 4 times less during
adolescence than during the preweanling period or adulthood (Spear, 2000). It is
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possible that decreased serotonergic activity across adolescence contributes to
heightened anxiety and hypersensitivity to mild stressors (Depue & Spoont,
1986). It is clear the 5-HT system undergoes many changes beginning at birth,
through childhood, adolescence, and into adulthood. Thus, the adolescent
serotonergic system remains increasingly vulnerable to pharmacological induced
neuronal changes (Chambers, Taylor, & Potenza, 2003).
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CHAPTER FIVE
NICOTINE

Introduction
Nicotine is a psychostimulant drug with strong addictive properties.
Nicotine is used in a variety of products, such as cigarettes, chewing tobacco,
snuff, nicotine gum or patches, and most recently electronic cigarettes
(Fagerstrom, Schneider, & Lunell, 1993; Farsalinos & Polosa, 2014; Hoffmann &
Hoffmann, 1997; Puri, Chaudhary, Srivastava, Tiwari, 2013). Of the various
nicotine products, cigarettes are the most popular, with worldwide cigarette
smoking resulting in about 6 million deaths a year, and is predicted to be the
cause of nearly 1 billion deaths within the 21st century (Farsalinos & Polosa,
2014; Yach, 2014). Lung cancer remains the leading cause of cancer related
deaths, in which 80-90% of lung cancer deaths are attributed to cigarette
smoking (Centers for Disease Control and Prevention [CDC], 2008; Henley et al.,
2014). In addition, cigarette smoking remains one of the most difficult stimulant
addictions to treat, with a relapse rate of around 90-95% in unaided quit attempts
within one year of the cessation date (Bancej, O’Loughlin, Platt, Paradis, &
Gervais, 2007; Hughes, Keely, & Naud, 2004; Lydon, Wilson, Child, & Geier,
2014; Van Zundert, Ferguson, Shiffman, & Engels, 2012).
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Mechanism of Action and Pharmacokinetics
When smoke particles containing nicotine are inhaled, nicotine is rapidly
absorbed through the lungs and into the bloodstream, where it quickly moves to
the brain (Benowitz, 2010; Weinberger & Sofuoglu, 2009). After crossing the
blood-brain barrier, nicotine binds to nAChRs (Clader & Yuguang, 2005; DajasBailador & Wonnacott, 2004; Dani & Bertrand, 2007). Increased ACh release
results in augmented release of other neurotransmitters, such as DA
(Benowitz, 2010). Nicotine-induced DA release from ventral tegmental area
neurons projecting to the nucleus accumbens are a pivotal component in
nicotine-induced pleasure and reward (Dani & De Biasi, 2001; Nestler, 2005;
Picciotto & Corrigall, 2002).
Nicotine augments the release of glutamate in the VTA, which promotes
the release of DA in the nucleus accmubens (Mansvelder & McGehee, 2000;
2002). Conversely, γ-aminobutyric acid (GABA) release in the VTA inhibits DA
release in the nucleus accmubens (Mansvelder & McGehee, 2000; 2002).
Continual binding of nicotine causes some of the nicotinic ACh receptors to
become desensitized (Mansvelder & McGehee, 2000; 2002). This desensitization
results in a diminished inhibition of DA release, while glutamate continues to
augment DA release (Benowitz, 2010; Mansvelder & McGehee, 2000; 2002).

Behavioral and Physiological Effects
Following cigarette smoking, a smoker will typically feel sensations of
stimulation and pleasure, as well as a reduction in stress and anxiety (Benowitz,
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2009). Additional behavioral effects of nicotine include augmented finger tapping,
focused and sustained attention, as well as improved reaction time, recognition
memory, and reasoning (Heishman, 1999). Physiological effects of nicotine
include decreases in body weight, as well as increases in heart rate and blood
pressure (Heishman, 1999; Omvik, 1996). When a smoker stops smoking, they
will often experience aversive withdrawal symptoms, such as anxiety, difficulty
concentrating, irritability, and restlessness (Benowitz, 2010; Heishman, 1999).
Therefore, smokers need nicotine to relieve aversive symptoms during
withdrawal (Jarvik, 1991). It is believed that chronic cigarette use is partly due to
this negative reinforcement (Jarvik, 1991).

Adolescent Cigarette Smoking
Cigarette smoking is most likely to begin during adolescence (Chen &
Kandel, 1995; Lantz, 2003). Among adult smokers within the United States,
nearly 90% of them began smoking before the age of 18 (CDC, 2013). The
prevalence rates for tobacco product use among middle school and high school
students are 6.7% and 23.3%, respectively (CDC, 2013). Additionally, the rate of
increase in cigarette smoking among adolescents is striking, with 3,000 American
children under the age of 18 beginning to smoke each day (Slotkin, 2002). This is
particularly concerning given that smoking is the main causal factor in nearly
30% of all cancer-related deaths (CDC, 2008; Henley et al., 2014).
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Nicotine as a Gateway Drug
Gateway theories of drug addiction propose that psychological and
neurobiological mechanisms of less deleterious drugs (e.g., nicotine or alcohol)
function as a gateway to more dangerous hard drugs of abuse (e.g.,
methamphetamine or cocaine) (Kandel & Faust, 1975; Lindsay & Rainey, 1997;
Nolley & Kelley, 2007; Weinberger & Sofuoglu, 2009). Indeed, among U.S. adults
(i.e., ages 18 to 34) who used cocaine in their lifetime, 87.9% smoked cigarettes
before their cocaine use (Kandel & Kandel, 2014). In contrast, 5.7% of adults
used cocaine and cigarettes at the same time, 3.5% of adults used cocaine first,
and 2.9% of cocaine users never smoked cigarettes (Kandel & Kandel, 2014).
With the recent rise in electronic cigarette use, especially among adolescents,
some researchers are suggesting the possibility of electronic cigarettes
functioning as a gateway for more traditional tobacco cigarettes (Bell & Keane,
2014).
Although the gateway theory of drug addiction is mostly accepted in
popular culture, it still remains debated within academic literature and
researchers in this field are careful not to express causal relationships between
the progressions from soft drugs to hard drugs (Bell & Keane, 2014). Rather, the
correlational relationship between this progression is typically expressed as
being strongly statistically linked (Lindsay & Rainey, 1997). In terms of the
gateway hypothesis, epidemiological studies are important for establishing the
sequence in which certain drugs may be used; however, it is imperative to
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employ animal models of addiction to make causal assertions about the
progression of one drug to another (Kandel & Kandel, 2014).

Adolescent Animal Studies
Adolescent animal models of smoking are essential to determine how
nicotine exposure can alter adolescent brain structure, functioning, and resulting
behavior. For example, adolescent nicotine exposure alters brain neurochemistry
when compared to adults (Shearman, Fallon, Sershen, & Lajtha, 2008).
Specifically, adolescent nicotine exposure induces greater extracellular levels of
dopamine and 5-HT in the nucleus accumbens (Shearman et al., 2008).
Comparing nicotine withdrawal in adolescent and adult rodents, adolescent
rodents show significantly less mecamylamine-induced withdrawal signs than
adults (Kota, Martin, & Damaj, 2008; O'Dell, Bruijnzeel, Ghozland, Markrou, &
Koob, 2004). These results suggest that adolescents display decreased
sensitivity to nicotine withdrawal, which by minimizing the aversive effects of
nicotine abstinence may maximize the reinforcing effects of nicotine during the
adolescent period (Kota et al., 2008; O'Dell et al., 2004). Further comparing
adolescent and adult nicotine-pretreated rodents, adolescent-pretreated rodents
display heightened nicotine reward sensitivity in adulthood, as compared to adultpretreated rodents tested on conditioned place preference (CPP) task (Adriani,
Deroche-Gamonet, Le Moal, Laviola, & Piazza, 2006; Kota et al., 2008).
Additionally, a single nicotine conditioning trial can elicit a CPP response in
adolescents, but not adults, suggesting that adolescents form associations more
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readily (Belluzzi, Lee, Oliff, & Leslie, 2004; Brielmaier, McDonald, & Smith,
2007). The results from these CPP experiments indicate that adolescent smokers
may be at a greater risk for nicotine addiction than individuals who start smoking
later in life (Adriani et al., 2006; Belluzzi et al., 2004; Brielmaier et al., 2007; Kota
et al., 2008). Similarly, comparing the self-administration of nicotine between
adolescent and adult rats, adolescent rats acquire more quickly and take higher
amounts of nicotine than adult rats, suggesting that nicotine is more reinforcing in
adolescent compared to adult rats (Chen, Matta, & Sharp, 2007; Levin, Rezvani,
Montoya, Rose, & Swartzwelder, 2003; but see Shram, Funk, Li, & Lê, 2008).
Lastly, adolescent mice have a greater preference for a nicotine and sucrose
solution than adults, further suggesting a heightened vulnerability to nicotine
(Adriani, Macrì, Pacifici, & Laviola, 2002).
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CHAPTER SIX
METHAMPHETAMINE

Introduction
Methamphetamine hydrochloride is a highly addictive and abused
psychostimulant classified as a schedule II controlled substance within the United
States (Calcaterra & Binswanger, 2013; Drug Enforcement Administration [DEA],
U.S. Department of Justice, 2003). methamphetamine is often sold illicitly and
used recreationally, with estimates of approximately 25 million methamphetamine
abusers worldwide (Panenka et al., 2013). This prevalence rate is greater for
both cocaine (i.e., ~14 million) and heroin (i.e., ~11 million) abusers (Panenka et
al., 2013).

Mechanism of Action and Pharmacokinetics
Methamphetamine enters the body typically through the lungs via
inhalation of smoke particles, although methamphetamine can be taken by a
number of routes, including sublingual, rectal, intranasal, intravenous injection,
subcutaneous injection, or solubilized and consumed orally as a liquid, but the
latter routes are not as common (Courtney & Ray, 2014; Novak & Kral, 2011;
Rusyniak, 2013). Once in the blood stream, methamphetamine travels to the
brain where it readily crosses the blood-brain barrier, due to its lipophilic structure
(Courtney & Ray, 2014; Rusyniak, 2013; Vearrier, Greenberg, Miller, Okaneku,
Haggerty, 2012).
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Within the CNS, methamphetamine functions as an indirect agonist, which
acts on DA, NE, 5-HT, and to a lesser extent glutamate neurotransmitter systems
in the nucleus accumbens (Cruickshank & Dyer, 2009; Nordahl, Salo, & Leamon,
2003). The impact of methamphetamine on reward occurs through an increase of
DA in the nucleus accumbens (Wise & Bozarth, 1984). Due to a similar molecular
structure, methamphetamine substitutes for the monoamine neurotransmitters
DA, NE, and 5-HT at their respective transporter sites (i.e., DAT, NET, and
SERT) (Cruickshank & Dyer, 2009; Rothman et al., 2001). Once in the cell,
methamphetamine induces changes in pH levels and the vesicle proton gradient,
so that newly synthesized monoamine neurotransmitter accumulates in the
cytosol of the presynaptic neuron (Courtney & Ray, 2014; Cruickshank & Dyer,
2009; Sulzer, Sonders, Poulsen, & Galli, 2005). Additionally, methamphetamine
alters the functioning of VMAT, aiding in the cytoplasmic accumulation of
monoamine neurotransmitters (Halpin, Collins, & Yamamoto, 2014).
Accumulation of excess monoamine neurotransmitters in the cytosol causes
DAT, NET, and SERT to actively pump DA, NE, or 5-HT into the synaptic cleft,
thus methamphetamine reverses the endogenous roles of these monoamine
transporters (Courtney & Ray, 2014; Cruickshank & Dyer, 2009; Rusyniak, 2013;
Sulzer et al., 2005; Vearrier et al., 2012).
In addition to increasing the release of monoamine neurotransmitters,
methamphetamine also attenuates the metabolism of DA, NE, and 5-HT by
inhibiting the enzyme MAO (Cruickshank & Dyer, 2009; Sulzer et al., 2005). This
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action produces a rapid accumulation of monoamine neurotransmitters in the
brain because MAO is inhibited from catabolizing DA, NE, and 5-HT (Meredith,
Jaffe, Ang-Lee, & Saxon, 2005; Rusyniak, 2013). Methamphetamine has longer
half-life of about 12 h, whereas cocaine has a shorter half-life (i.e., 90 min)
(Rawson et al., 2000).

Behavioral and Physiological Effects
Acute effects of methamphetamine are generally linked with feelings of
euphoria, invincibility, increased energy, wakefulness, and heightened sexual
experiences (Cruickshank & Dyer, 2009; Russell et al., 2008; Vearrier et al.,
2012). However, continued methamphetamine use can become harmful and
typically effects physical and psychological processes, causing confusion,
tremors, convulsions, anxiety, aggressiveness, hallucinations, and paranoia
(Russell et al., 2008; Vearrier et al., 2012). Prolonged methamphetamine use
results in increased cravings leading to chronic use (Russell et al., 2008; Vearrier
et al., 2012). The effects of chronic methamphetamine use are characterized by
neurotoxicity and major depressive disorder, with the potential for suicidal
ideation and action (Russell et al., 2008; Vearrier et al., 2012).
Methamphetamine abuse may result in a wide range of complications,
such as cardiovascular, dermatological, hematological, gastrointestinal,
genitourinary, musculoskeletal, neurological, psychiatric, and pulmonary
problems, as well as renal failure, perinatal maternal death, and premature death
(Russell et al., 2008; Vearrier et al., 2012). In addition to these complications,
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methamphetamine addiction also serves as a serious public health problem
because of the crime and violence associated with methamphetamine abuse
(Vearrier et al., 2012). Due to the highly addictive nature of methamphetamine,
negative treatment outcomes and relapse are often expected for
methamphetamine addictions (Vearrier et al., 2012). Many of the psychosocial
interventions for methamphetamine dependence are riddled with poor entrance
and retention rates (Shearer, 2007). There currently are no
psychopharmacological treatments approved by the U.S Food and Drug
Administration for methamphetamine dependence, although several medications
are currently under study (Courtney & Ray, 2014).

Adolescent Methamphetamine Use
In terms of the United States, a 2012 report from the Substance Abuse
and Mental Health Services Administration (SAMHSA) found that approximately
12 million (~ 4.7 %) Americans aged 12 and older have tried methamphetamine
in their lifetime (Courtney & Ray, 2014; SAMHSA, 2013). Additionally, about 1.2
million have reported using methamphetamine in the last year, and around
440,000 have used methamphetamine in the last month (Courtney & Ray, 2014;
SAMHSA, 2013). Among high school students, a Monitoring the Future survey
found that 1.6% had used methamphetamine in 2010 (Panenka et al., 2013).
Additionally, adolescent methamphetamine use is particularly common in the
western regions of the United States and Canada (Gruenewald, Johnson,
Ponicki, Remer, & Lascala, 2010; Rawson, Anglin, & Ling, 2002).
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Methamphetamine and Nicotine
Simultaneous psychostimulant and nicotine use is highly prevalent (Brecht
et al., 2004). Indeed, cocaine users reported increased rates of cigarette use (7080%) and nicotine dependence (50%) compared to the general population (22%
and 13%, respectively) (Grant, Hasin, Chou, Stinson, & Dawson, 2004; Kalman,
Morissette, & George, 2005; Patkar et al., 2006). The co-morbidity rates of
methamphetamine use and cigarette smoking are even higher (87-92%) (Baker
et al., 2004; Grant et al., 2007).
In regards to cigarette smoking and treatment of other stimulant addictions
(e.g., cocaine or methamphetamine), it is clear users are motivated to quit;
however, smoking cessation rates are low (~12 %) (Campbell, Wander, Stark, &
Holbert, 1995; Weinberger & Sofuoglu, 2009). Due to mixed reports, it is unclear
whether concurrent cigarette smoking and other stimulant use is detrimental to
drug treatment outcomes (Weinberger & Sofuoglu, 2009). Some clinical reports
suggest that use of nicotine-containing products may facilitate the onset of
methamphetamine relapse in addicts, thus the management of nicotine intake
should be considered in clinical settings (Berry et al., 2012). Similarly, self-report
studies show that cocaine-dependent individuals report stronger cocaine
cravings following nicotine treatment (Reid, Mickalian, Delucchi, Hall, & Berger,
1998), whereas the nicotine antagonist, mecamylamine, reduces cocaine craving
in cocaine-dependent individuals (Reid, Mickalian, Delucchi, & Berger, 1999). In
contrast, other clinical reports suggest concern that cessation of nicotine-
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containing products may increase the risk of relapse to other stimulants, such as
methamphetamine or cocaine (Weinberger & Sofuoglu, 2009). The potential for
cigarette smoking to produce neurological changes that facilitate the initiation
and augmentation of methamphetamine or cocaine use is concerning. In order to
further investigate this relationship, it is necessary to turn to animal models of
addiction.

Psychostimulant and Nicotine Animal Studies
Periadolescent rats pretreated with nicotine for 7 days and subsequently
challenged with cocaine or amphetamine on the following day, display
heightened locomotor activity when compared to adult rats (Collins &
Izenwasser, 2004; Collins, Montano, & Izenwasser, 2004). These results suggest
that adolescent nicotine exposure creates a greater risk for cocaine or
amphetamine abuse in adolescence as compared to adulthood (Collins &
Izenwasser, 2004; Collins et al., 2004). Relatedly, adolescent nicotine
pretreatment enhances the acquisition of cocaine self-administration when
compared to adults, further indicating the susceptibility of the adolescent brain to
the effects of nicotine on subsequent stimulant use (McQuown, Belluzzi, & Leslie,
2007). Rats treated with nicotine for 10 days during adolescence engaged in
more cocaine seeking following cocaine-induced reinstatement in adulthood,
suggesting that nicotine exposure in adolescence may alter the vulnerability for
cocaine relapse in adulthood (Anker, & Carroll, 2011).
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When considering the role of nicotine treatment on methamphetamine
self-administration, rats that received nicotine treatment in adolescence through
adulthood received more methamphetamine infusions when compared to rats
treated with saline (Pipkin et al., 2014). Thus, continuous nicotine exposure
beginning in adolescence through adulthood enhances the reinforcing effects of
methamphetamine. In addition, nicotine-pretreated adolescent rats received
more methamphetamine intake in adulthood than saline-pretreated adolescent
rats (Pipkin et al., 2014). Thus, adolescent nicotine pre-exposure increases the
reward potential of methamphetamine in adulthood.
In regards to the role of nicotine on methamphetamine relapse, nicotine
treatment in adolescent rats does not alter methamphetamine-induced
reinstatement in adults (Pipkin et al., 2014). Thus, adolescent nicotine exposure
does not affect methamphetamine seeking and relapse in adulthood. In contrast,
5 days of nicotine treatment during extinction attenuates methamphetamine
reinstatement in adult rats, suggesting that in certain experimental conditions,
nicotine treatment reduces methamphetamine seeking and attenuate the risks
associated with relapse (Hiranita, Anggadiredja, Fujisaki, Wantanabe, &
Yamamoto, 2004; Hiranita, Nawata, Sakimura, Anggadiredja, & Yamamoto,
2006; Hiranita, Nawata, Sakimura, & Yamamoto, 2008). The difference in
methamphetamine reinstatement findings may be due to age and/or duration of
nicotine treatment. Despite opposing directions between nicotine and
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methamphetamine self-administration and reinstatement data, it is clear that a
relationship between the two drugs exists.
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CHAPTER SEVEN
SELF-ADMINISTRATION

Introduction
The drug self-administration paradigm has been widely used since the
1960’s and functions as an operant conditioning procedure used to study reward
and addiction behavior (Deneau, Yangita, & Seevers, 1969; Thompson &
Schuster, 1964; Weeks, 1962). Self-administration examines whether the effects
of a drug will reinforce a certain behavior, such as pressing a lever for a drug
injection (Balster & Schuster, 1973; Stoops, 2008).
Self-administration can be used on animal or human subjects and can
utilize different routes of administration, such as insufflation, oral ingestion,
inhalation, or intragastric infusion, as well as intramuscular, intravenous,
intraperitoneal, or intracerebral injections (Gardner, 2000; Panlilio & Goldberg,
2007). Intravenous injections and oral ingestion are the most typically used
routes of administration (Gardner, 2000; Panlilio & Goldberg, 2007); however,
intravenous injections and inhalation are the faster routes of delivery and,
therefore, produce stronger reinforced behaviors (Gardner, 2000; Panlilio &
Goldberg, 2007).
The drug self-administration paradigm relies on operant conditioning
principles, with the main assumption that drugs serve as reinforcers, thus
increasing the likelihood of a certain behavior that is paired with the effects of a
drug (Edwards & Koob, 2013; Panlilio & Goldberg, 2007). The response and
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reinforcement relationship (i.e. pushing a lever for a drug injection) can be further
manipulated by using different schedules of reinforcement, such as requiring a
certain number of responses or amount of time to pass before the subject
receives the reinforcing effects of the drug (Haney & Spealman, 2008; Spealman
& Goldberg, 1978; Stoops, 2008). One of the most simple and extensively used
schedules of reinforcement is continuous reinforcement, where the subject is
reinforced for every response given (Domjan, 2005; Gál & Gyertyán, 2003;
Minhas & Len, 2014; Panlilio & Goldberg, 2007). This schedule is results in a
dose-dependent manner; with higher doses resulting in less frequent responses
(Panlilio & Goldberg, 2007). Continuous reinforcement does not typically
correspond to behavior in a natural context, because an oragnism must often
work for a reward, or wait a given amount of time to receive a reinforcing stimulus
(Domjan, 2005; Panlilio & Goldberg, 2007).
Ratio schedules require that a certain number of responses to pass before
the subject receives the reinforcer (Domjan, 2005; Haney & Spealman, 2008;
Panlilio & Goldberg, 2007; Spealman & Goldberg, 1978). In fixed-ratio (FR)
scheduling, the subject receives the reinforcer after a certain number of
responses. FR schedules typically produce high, steady rates of responding, with
a brief pause in responding after the reinforcer is given (Domjan, 2005; Panlilio &
Goldberg, 2007; Spealman & Goldberg, 1978). FR scheduling is often used to
determine the reinforcing effects of long-lasting drugs that may result in an
infrequent self-administration rate over time (Panlilio & Goldberg, 2007).
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Typically, an FR 1 schedule (i.e., continuous reinforcement) is used for initial selfadministration training (Panlilio & Goldberg, 2007). When an animal has
established consistent responding for reinforced drug delivery, the ratio can be
increased sequentially (i.e., FR 2, FR 5, etc.) (Panlilio & Goldberg, 2007).
FR schedules of reinforcement are utilized in drug self-administration with
laboratory animals, including cocaine, amphetamine, methamphetamine,
caffeine, opiates, ethanol, and other addictive compounds (Balster, Kilbey, &
Ellinwood, 1976; Deneau et al., 1969; Goldberg, 1973; Winger & Woods, 1973).
When animals are given unlimited access to stimulants, such as cocaine,
amphetamine, methamphetamine, methylphenidate, or caffeine, it produces
increased periods of alternating consumption and abstinence (Deneau et al.,
1969; Johanson, Balster, & Bonese, 1976; Pickens & Harris, 1968; Yokel &
Pickens, 1973). This is similar to what is observed in the human condition, with
periods of binging and abstinence (Kramer, Vitezslav, & Littlefield, 1967). When
given a reinforcement schedule that allows limited drug access, stimulant selfadministration produces smaller binges at the beginning of the session, and
consistent drug intake throughout the remainder of the session (Gardner, 2000).

Reinstatement and Relapse
Reinstatement of a drug is used to model drug relapse after a period of
abstinence (Bossert, Marchant, Calu, & Shaham, 2013; Sanchis-Segura &
Spanagel, 2006). After multiple extinction sessions, the subject is then either reexposed to the original or different reinforcing drug, presented with drug47

associated cues, or given foot shock stress within the self-administration
chamber (Bossert et al., 2013; Sanchis-Segura & Spanagel, 2006). These types
of treatments are meant to model triggers associated with relapse in humans
(Bossert et al., 2013; Sanchis-Segura & Spanagel, 2006).

Advantages and Disadvantages of Intravenous Self-Administration
Given the various schedules and manipulations used in the drug selfadministration paradigm, it is clear that self-administration models many aspects
of human addiction. When compared to other behavioral paradigms, selfadministration represents the highest point-to-point correspondence with
addictive behaviors observed in the natural environment (Panlilio & Goldberg,
2002). Therefore, self-administration procedures maintain a very high level of
face validity, reliability, and species generality (Haney & Spealman, 2008). In
regards to predictive validity, drug self-administration in animals predicts the
abuse potential of new compounds in humans (Balster, 1991; Lile & Nader,
2003). Self-administration procedures are often conducted via nose-poke holes
or levers (Gardner, 2000). One advantage to using nose-pokes is that they are
an innate behavior for rodents, whereas lever pressing is a learned behavior that
can be time consuming.
A limitation for the drug self-administration paradigm is expense in both
time and other resources (Panlilio & Goldberg, 2002). Due to its complexity, the
self-administration procedure may, in some cases, be less productive than
simpler behavioral paradigms when screening for novel drugs or relating
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addiction-like behaviors to neural circuitry (Panlilio & Goldberg, 2002). An
additional limitation of intravenous self-administration is unique to ontogeny.
Specifically, adolescent rats can quickly outgrow the implanted cannulas
because of the normal growth that occurs during this developmental period. More
importantly, because of the recovery time required after surgery, it is difficult to
complete intravenous self-administration procedures during the short time span
of adolescence. One way to avoid these problems is to change the route of drug
administration.

Oral Self-Administration
Oral self-administration can be established in many different animals with
a number of abused drugs (e.g., alcohol, opiates, and psychostimulants)
(Meisch, 2001). Following a response (i.e., nose-poke or lever press), rats are
presented with a spigot, to which they can lick a drug solution (Gardner, 2000).
An automated device then measures individual licks taken by the rat (Gardner,
2000). Another form of oral self-administration that does not make use of operant
reinforcement procedures involves giving rats free access to two water bottles for
a specified period of time, one containing vehicle and the other containing a
solution of the drug of interest (Collins, Pogun, Nesil, & Kanit, 2012). The water
bottles are then weighed and the preferred solution is determined (Collins et al.,
2012).
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Advantages and Disadvantages of Oral Self-Administration
The main advantage of the oral route of self-administration is that surgery
is not necessary and there is no need for catheters, which avoids infection,
obstruction, and incorrect placement (Macenski & Meisch, 1994). Additionally,
the surgical procedures limit the amount of time an animal can be used in a given
experiment (Macenski & Meisch, 1994).
The main disadvantages of the oral route of self-administration include the
lack of drug absorption resulting from chemical polarity, as well as the
degradation of drugs via digestive enzymes and alternating pH levels (Turner,
Brabb, Pekow, & Vasbinder, 2011). Other limitations include first pass effects by
the liver, delayed time for drugs to reach the CNS and produce behavioral
effects, the aversive taste of many drugs, and the small amounts of drug volume
consumed per drinking episode (Macenski & Meisch, 1994; Meisch, 2001; Turner
et al., 2011). Regardless of the possible limitations, laboratory animals have
learned to orally self-administer using alcohol, cocaine, amphetamine,
methamphetamine, and other psychoactive drugs (Meisch, 2001; Shabani et al.,
2013).
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CHAPTER EIGHT
THESIS PROPOSAL AND HYPOTHESES

Adolescence is a vulnerable period in development, especially in regards
to pharmacologically-induced changes in neurochemistry and resulting behavior
(Stanis & Andersen, 2014). Cigarette smoking is most likely to begin during
adolescence and can often serve as a gateway to other drugs of abuse
(Lewinsohn et al., 1999). Adolescent methamphetamine use is also common,
with about 1.6% of high school students having used methamphetamine in 2010
(Panenka et al., 2013). Simultaneous nicotine and methamphetamine use is very
prevalent, with an estimate that 97% of methamphetamine users also use
nicotine (Brecht et al., 2004). Nicotine and methamphetamine have comparable
effects on neural reward pathways, such as increasing DA in the nucleus
accumbens (Dani & De Biasi, 2001; Nestler, 2005; Picciotto & Corrigall, 2002;
Wise & Bozarth, 1984). When administered together, nicotine and
methamphetamine display variable effects on reward-related behaviors (Hiranita
et al., 2004; Neugebauer et al., 2010; Pipkin et al., 2014). The effects of nicotine
and methamphetamine co-treatment have been seldom investigated, with little
known about how these drugs interact in adolescent populations.
Animal studies have shown a potential connection between nicotine and
methamphetamine. For example, nicotine can be substituted for
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methamphetamine in a discrimination procedure, which suggests that the two
drugs possess similar properties (Gatch, Flores, & Forster, 2008). In mice,
repeated nicotine treatment produces locomotor cross-sensitization when given a
methamphetamine challenge (Kuribara, 1999). Thus, repeated cigarette smoking
may increase the rewarding potential of initial methamphetamine use.
Interestingly, the same study found that coadministration of methamphetamine
and a high dose of nicotine reduced the induction of methamphetamine
sensitization, suggesting that nicotine, in some cases, may contain protective
properties against methamphetamine abuse potential (Kuribara, 1999).
In contrast to findings of nicotine and methamphetamine crosssensitization, prior nicotine exposure does not have an effect on
methamphetamine CPP, extinction, or reinstatement, indicating that nicotine may
not be responsible for an enhancement of the rewarding effects of
methamphetamine (Berry et al., 2012). Although CPP and self-administration can
both model the rewarding effects of certain drugs, it is evident that
neuropharmacological mechanisms underlying the paradigms are dissociable
(Bardo & Bevins, 2000). Thus, in rats previously trained to self-administer
methamphetamine, nicotine exposure produces methamphetamine reinstatement
(Neugebauer et al., 2010), suggesting that nicotine exposure during a withdrawal
period may facilitate the onset of methamphetamine relapse. Methamphetamine
pretreatment increases nicotine self-administration (Rauhut, Neugebauer,
Dwoskin, & Bardo, 2003), further connecting the rewarding properties of the two
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psychostimulants. Prenatal nicotine exposure produces heightened
methamphetamine infusions in adulthood, which is congruent with the notion that
early developmental nicotine exposure can enhance methamphetamine reward
later in life (Lacy, Morgan, & Harrod, 2014). Thus, preclinical evidence suggests
that nicotine exposure can augment the rewarding and abuse potential of
methamphetamine in certain experimental conditions (e.g., self-administration,
behavioral-sensitization); however, this effect is not observed in others (e.g.,
CPP).
As for adolescent nicotine exposure on methamphetamine selfadministration in early adulthood, a low dose of nicotine treatment beginning in
adolescence through adulthood augmented methamphetamine infusions (Pipkin
et al., 2014), suggesting that a moderate amount of smoking during adolescence
through adulthood may enhance the reinforcing effects of methamphetamine. In
addition, nicotine-pretreated adolescent rats received more methamphetamine
intake in adulthood than saline-pretreated adolescent rats (Pipkin et al., 2014).
Thus, adolescent cigarette smoking may increase the reward potential of
methamphetamine in adulthood.
In regards to methamphetamine withdrawal and relapse, adolescent
nicotine exposure had no effect on methamphetamine extinction or reinstatement
in adult rats (Pipkin et al., 2014). Therefore, adolescent cigarette smoking may
not alter methamphetamine seeking and relapse in adulthood. Alternatively, a
high dose of nicotine exposure during a 5-day methamphetamine withdrawal
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period attenuated lever-responding in adult rats following a single
methamphetamine priming injection (Hiranita et al., 2004; 2006), suggesting that
nicotine exposure, under certain experimental conditions, can reduce
methamphetamine seeking and risk associated with relapse. It is evident that the
effects of adolescent or adult nicotine exposure on methamphetamine selfadministration, extinction, and reinstatement vary widely based on various
experimental procedures and design (i.e., age of animal, dose, and behavioral
paradigm).
Lastly, there is clear pre-clinical evidence suggesting sex differences exist
in regards to the reinforcing properties of nicotine or methamphetamine. During
nicotine self-administration, female rats maintain a higher motivation to obtain
nicotine than male rats, while no sex differences are observed during nicotineinduced reinstatement (Donny et al., 2000; Feltenstein, Ghee, & See, 2012).
Similar to the sex differences observed within nicotine self-administration, female
rats are more susceptible to the reinforcing properties of methamphetamine than
male rats. Specifically, female rats acquire methamphetamine self-administration
more readily than male rats (Kucerova, Vrskova, & Sulcova, 2009; Reichel,
Chan, Ghee, & See, 2012; Roth & Carroll, 2004; Ruda-Kucerova et al., 2015).
During methamphetamine reinstatement, female rats respond more for access to
methamphetamine than male rats (Ruda-Kucerova et al., 2015). Given the
distinct differences between male and female rats observed within nicotine or
methamphetamine reinforcement procedures, it is possible that sex may alter
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adolescent nicotine exposure-induced changes on methamphetamine selfadministration, extinction, and reinstatement.
The aim of the present investigation was to gain a further understanding
about the effects of nicotine exposure on the reinforcing properties of
methamphetamine during adolescence. To this end, we assessed
methamphetamine acquisition, extinction, and reinstatement in adolescent male
and female rats. Employing an oral self-administration procedure allowed us to
test rats during this pivotal developmental period. Moreover, this method
shortened training time and omitted surgical procedures, which allowed for the
testing of a large number of subjects and a more complicated research design.
The PD 25 to PD 65 age range was selected to approximate adolescence
(Spear, 2000), which the oral self-administration paradigm was used to model
human addiction. A total of seven treatment groups were used in order to
precisely determine whether nicotine exposure enhances or diminishes the
reinforcing effects of methamphetamine during the adolescent period. On PD 25,
adolescent male and female rats were injected with saline or nicotine (0.16 or
0.64 mg/kg, sc) once a day for 10 days until PD 34. Subsequently, half of the
nicotine-pretreated rats continued to receive nicotine at the same doses, while
the other half received saline for the remainder of the experiment. In addition,
one third of the saline pretreated rats continued to receive saline, while two thirds
received nicotine (0.16 or 0.64 mg/kg) for the remainder of the experiment (see
Figure 1). On PD 35, rats underwent training to nose poke for a 10% sucrose
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solution. After reaching sucrose-training criteria, methamphetamine acquisition
occurred across seven different 2 h sessions. When criteria were met, rats began
extinction training, where nose poke responses were not reinforced. Once
extinction criteria were met, all rats were given a priming injection of
methamphetamine (1.0 mg/kg) in order to induce reinstatement of
methamphetamine responding.

Figure 1. Project design and timeline.
Overall, we had two primary hypotheses about how nicotine and sex
would affect oral methamphetamine self-administration:
First, we predicted that nicotine exposure would alter consumption and
responding for methamphetamine. We hypothesized that exposure to a low dose
of nicotine (0.16 mg/kg) would enhance consumption and responding for
methamphetamine. In contrast, we hypothesized that exposure to a high dose of
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nicotine (0.64 mg/kg) would attenuate consumption and responding for
methamphetamine. These hypotheses were founded in past research showing
that exposure to low doses of nicotine potentiates the rewarding properties of
methamphetamine or cocaine (McQuown et al., 2007; Pipkin et al., 2014),
whereas exposure to higher doses of nicotine attenuates methamphetamine selfadministration and reinstatement (Hiranita et al., 2004; 2006; Neugebauer et al.,
2010).
Second, we predicted that sex would also alter consumption and
responding for methamphetamine. We hypothesized that female rats would have
enhanced consumption and responding for methamphetamine. These
hypotheses were founded in past research showing that female rats acquire
methamphetamine self-administration more readily (Kucerova, Vrskova, &
Sulcova, 2009), as well as respond more for access to methamphetamine during
reinstatement than male rats (Ruda-Kucerova et al., 2015). Moreover, we
hypothesized that female rats would show larger changes in responding for
methamphetamine and consumption at both doses of nicotine.
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Table 1. Hypothesized Main Effects and Interactions for Nicotine (0.16 or 0.64
mg/kg) Treatment and Sex (Male or Female) Across Methamphetamine SelfAdministration, Extinction, and Reinstatement.
Low Dose (0.16 mg/kg)
Sex
Main Effect
Pre- or Post-Treatment
Main Effect
Sex × Pre- or Post-Treatment
Interaction
Pre- × Post-Treatment
Interaction
Sex × Pre- and Post-Treatment
Interaction

Female > Male
Nicotine (0.16 mg/kg) > Saline
Female (0.16 mg/kg) > Female Saline
Female (0.16 mg/kg) > Male (0.16 mg/kg) or Saline
0.16-0.16 > SAL-SAL, 0.16-SAL, SAL-0.16
Female (0.16-0.16) > Female (SAL–SAL; 0.16–SAL; SAL–0.16)
Female (0.16-0.16) > Male (SAL–SAL; 0.16–SAL; SAL–0.16;0.16-0.16)
High Dose (0.64 mg/kg)

Sex
Main Effect
Pre- or Post-Treatment
Main Effect
Sex × Pre- or Post-Treatment
Interaction
Pre- × Post-Treatment
Interaction
Sex × Pre- and Post-Treatment
Interaction

Female > Male
Saline > Nicotine (0.64 mg/kg)
Male (0.64 mg/kg) < Male Saline
Male (0.64 mg/kg) < Female (0.64 mg/kg) or Saline
SAL-SAL > 0.64-0.64, 0.64-SAL, SAL-0.64
Male (0.64-0.64) < Male (SAL–SAL; 0.64–SAL; SAL–0.64)
Male (0.64-0.64) < Female (SAL–SAL; 0.64–SAL; SAL–0.64; 0.64-0.64)
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CHAPTER NINE
MATERIALS AND METHODS

Subjects
Subjects were 164 young male and female rats (n = 911) of SpragueDawley descent (Charles River, Hollister, CA). Four subjects were found to be
statistical outliers and removed from data analyses. Rats were housed with the
dam until being weaned on PD 23, after which they were housed with same-sex
littermates in large maternity cages. Food and water were provided ad-libitum,
except as noted below. The colony room was maintained at 2123 C and kept
under a 12 L:12 D cycle. Rats were tested in a quiet, separate room during the
light phase of the cycle. Subjects were cared for according to the “Guide for the
Care and Use of Mammals in Neuroscience and Behavioral Research” (National
Research Council, 2010) under a research protocol approved by the Institutional
Animal Care and Use Committee of CSUSB.

Apparatus
Behavioral testing occurred in standard operant chambers (Coulbourn
Instruments, Whitehall, PA). Each chamber contained two nose poke
operandums (2 cm from the floor), an optical lickometer, a house light, a stimulus
light, and a sound cue (500 Hz, 10 dB above background). The two nose poke
operandums were positioned on the front wall of the chamber, with the optical
lickometer positioned between the two nose poke operandums. The stimulus
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light and sound cue were located directly above the active nose poke hole. The
location of the active nose poke hole was counterbalanced across all selfadministration chambers on either the left or right side of the optical lickometer.
Nose pokes in the active nose poke hole resulted in rats receiving access to a
reinforcer (e.g., sucrose or methamphetamine) for 30 s. Nose pokes in the
inactive nose poke hole resulted in no scheduled consequences. The house light
was located on the rear wall of the chamber and remained on while rats were
inside the operant chambers, except during timeout periods, wherein the house
light was turned off for 20 s. Each chamber was housed in a soundproof isolation
cubicle and controlled by an IBM compatible computer interfaced with a data
collection program (Graphic State, Coulbourn Instruments).

Drugs
(−)-Nicotine hydrogen tartrate and (±)-methamphetamine hydrochloride
(Sigma-Aldrich, St. Louis, MO) was dissolved in saline. Nicotine injections were
administered subcutaneously (SC), whereas methamphetamine injections were
administered intraperitoneally (IP). Methamphetamine and sucrose were
dissolved in distilled water for drinking solutions.

Procedures
In Vivo Drug Treatment
Starting on PD 25, rats were weighed and then injected with nicotine (0.16
or 0.64 mg/kg) or saline for 10 consecutive days until PD 34 (see Figure 2). This

60

injection period (PD 25−PD 34) is developmentally comparable to early
adolescence in humans (Anderson, 2003). On PD 35, rats in the 0.16 and 0.64
mg/kg pretreatment groups were evenly divided and assigned to a group that
either continued to receive the same nicotine dose they received as adolescents
or saline. Rats that had received saline as adolescents were divided into three
equal groups, where they received 0.16 or 0.64 mg/kg nicotine or continued to
receive saline injections. Drug treatments starting on PD 35 continued until the
end of the experiment. In total, there were 7 drug groups: SAL–SAL, 0.16–0.16,
0.16–SAL, SAL–0.16, 0.64–0.64, 0.64–SAL, SAL0.64.
Nose Poke Training
Starting on PD 33, rats were pre-exposed to a 10% sucrose solution for 32
h in their home cage. On PD 35, rats were placed in a self-administration
chamber and allowed to nose poke for access to a 10% sucrose (w/v) solution on
an FR1 schedule for 60 min each day until a criterion of ≥ 10 presentations for 2
consecutive days was met. Following each session, rats were treated with
nicotine (0.16 or 0.64 mg/kg) or saline in their home cage. Nose poke responses
in the active hole resulted in the simultaneous presentation of a stimulus light,
sound cue (500 Hz, 10 dB above background), and a 30 s presentation of a liquid
dropper (i.e., reinforcement period). After each liquid dropper presentation, the
active nose poke hole became inactive for 20 s, which was indicated by the
absence of the house light (i.e., timeout period). On training days, water
availability was restricted for 16 hr/day to accelerate acquisition of operant
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responding. Following nose poke training, rats were food restricted to 90% of
their free-feeding weight for the remainder of the experiment, while water was
made available ad-libitum. Rats that failed to meet training criterion were
excluded from the study.
Methamphetamine Self-Administration
Once the sucrose-training criterion was met, methamphetamine fade-in
and sucrose fade-out began across seven (2 h) sessions (adopted from Shabani
et al., 2013; see Figure 2). Each nose poke response in the active hole resulted
in the simultaneous presentation of a stimulus light, sound cue (500 Hz, 10 dB
above background), and a 30 s presentation of a liquid dropper that delivered
either a sucrose, methamphetamine, or sucrose and methamphetamine solution
(i.e., reinforcement period). After each liquid dropper presentation, the active
nose poke hole became inactive for 20 s, which was indicated by the absence of
the house light (i.e., timeout period). During sessions 12 liquid solutions were
presented on an FR1 schedule; during sessions 37 liquid solutions were
presented on an FR2 schedule. The criterion for sessions 16 was ≥ 10
presentations for each 2 hr session. Sessions 1 and 3 required a criterion of ≥ 10
presentations for 2 consecutive days. Rats were exposed to session 7 for three
consecutive days. If rats did not meet criteria for a particular session, then rats
remained on that session at least 4 days, after which they were advanced to the
next session.
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Session 1 served as a baseline, in which a 10% sucrose solution was
presented alone. On session 2, methamphetamine fade-in and sucrose fade-out
began. Specifically, a low dose of methamphetamine (20 mg/l) was introduced
into an 8.5% sucrose solution. On sessions 36, a high dose of
methamphetamine (40 mg/l) was introduced into the sucrose solutions (i.e., 6.5%
for session 3, 4.5% for session 4, 2.5% for session 5, and 0.5% for session 6).
On session 7, no sucrose was present in the methamphetamine (40 mg/l) liquid
solution (see Figure 2).

Figure 2. Methamphetamine acquisition
Extinction Training
Extinction training began following methamphetamine (40 mg/l) acquisition
(see Figure 1). During extinction, rats underwent 2 h training sessions, in which
nose poke behavior resulted in no scheduled consequences, but responses were
recorded. Rats remained in extinction for 7 consecutive days or until active nose
poke responses were < 10% of the last day of FR2 methamphetamine (40 mg/l)
acquisition for two consecutive days.
Drug Prime Reinstatement
Once extinction criteria were met, all rats were given a priming injection of
methamphetamine (1.0 mg/kg, IP) 5 min before being placed in the self-
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administration chambers (see Figure 1). Reinstatement sessions lasted 2 h,
during which nose pokes resulted in no consequences.

Data Analysis
Data for acquisition, extinction, and reinstatement sessions were collected
using Graphic State program software (Coulbourn Instruments). Total active and
inactive nose pokes, active and inactive nose pokes during the timeout period,
active nose pokes during the reinforcement period, and amount of volume
consumed (i.e., sucrose and/or methamphetamine) were recorded and
calculated for all acquisition and self-administration sessions. Total active and
inactive nose pokes were recorded and calculated for all extinction and
reinstatement sessions. Data from rats exposed to a low dose of nicotine (0.16
mg/kg) or a high dose of nicotine (0.64 mg/kg) were analyzed separately. Thus,
all data from methamphetamine self-administration and reinstatement sessions
were analyzed by 2×2×2 ANOVAs (sex × pre-treatment × post-treatment).
Acquisition training data (sucrose training – session 6) were analyzed with mixed
between-within ANOVAs, with session as the within subjects variable and sex,
pre-treatment, and post-treatment as the between subjects variables (session ×
sex × pre-treatment × post-treatment). Extinction data were analyzed with mixed
between-within ANOVAs, with day as the within subjects variable and sex, pretreatment, and post-treatment as the between subjects variables (day × sex ×
pre-treatment × post-treatment). If needed, data were further analyzed with oneway ANOVAs. In addition, body weight data were analyzed with mixed between64

within ANOVAs, with day as the within subjects variable and sex, pre-treatment,
and post-treatment as the between subjects variables (day × sex × pre-treatment
× post-treatment). If the assumption of sphericity was violated, then the
Greenhouse-Geisser correction was used. Post hoc comparisons were made
with Tukey tests, p < .05.
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CHAPTER TEN
RESULTS

Effects of Nicotine (0.16 mg/kg) Exposure on Oral Methamphetamine SelfAdministration, Extinction, and Reinstatement
Effect of Nicotine (0.16 mg/kg) Exposure on Bodyweight
Adolescent nicotine (0.16 mg/kg) exposure across the pre- (PD 25−PD 34)
and post-treatment (PD 35−54) phases did not alter bodyweights of either male
or female rats. Bodyweights of all rats progressively increased across the pre(PD 25−PD 34) and post-treatment (PD 35−54) periods [day main effect,
F(1.99,1.63.96) = 696.69, p > .001] (see Figure 3). Male rats (M = 175.80, SEM =
2.70) weighed more than female rats (M = 143.75, SEM = 2.81) across the preand post-treatment periods [sex main effect, F(1,75) = 67.64, p > .001] (see
Figure 3).
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Figure 3. Mean body weight (± SEM) of male and female rats exposed to saline
(SAL) or nicotine (0.16 mg/kg) during the pre- (PD 25–34) or post-treatment (PD
35–~60) phases.
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Acquisition of Methamphetamine Self-Administration
Oral methamphetamine self-administration was acquired over six training
sessions, in which sucrose was phased out and methamphetamine was
introduced. On session 7, rats responded for methamphetamine alone. In
general, neither pre- nor post-treatment with nicotine (0.16 mg/kg) altered
consumption or responding for methamphetamine (see Figure 4). However, rats
exposed to saline during the pre-treatment period had more inactive nose pokes
within the timeout period than rats exposed to nicotine (0.16 mg/kg) during the
pre-treatment period [pre-treatment main effect, F(1,75) = 7.02, p < .01] (see
Figure 5D).
Sex did not alter consumption or responding for methamphetamine during
the first six sessions (see Figure 4); however, female rats had more active nose
pokes during the timeout period than male rats across methamphetamine
acquisition training [sex main effect, F(1,75) = 5.12, p < .05] (see Figure 5B &
6A). In addition, female rats had more total inactive nose pokes than male rats
across methamphetamine acquisition training [sex main effect, F(1,75) = 12.70,
p < .001] (see Figures 5C & 6B). Lastly, female rats had more inactive nose
pokes during the timeout period than male rats [sex main effect, F(1,75) = 7.95,
p < .01] (see Figures 5D & 6C).
None of the remaining dependent measures (i.e., total active nose pokes)
were altered by nicotine (0.16 mg/kg) or sex (see Figure 5).
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Figure 4. A) Mean sucrose and methamphetamine consumption; and B) mean
number of active nose pokes (reinforcement) (± SEM) for male and female rats
on the last day of behavioral responding across methamphetamine acquisition
training sessions (sucrose training–session 6). Rats were exposed to saline
(SAL) or nicotine (0.16 mg/kg) during the pre- (PD 25–34) or post-treatment (PD
35–~60) periods.
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Figure 5. A) Mean number of active nose pokes (total); B) mean number of active
nose pokes (timeout); C) mean number of inactive nose pokes (total); and D)
mean number of inactive nose pokes (timeout) (± SEM) for male and female rats
on the last day of behavioral responding across methamphetamine acquisition
training sessions (sucrose training–session 6). Rats were exposed to saline
(SAL) or nicotine (0.16 mg/kg) during the pre- (PD 25–34) or post-treatment (PD
35–~60) periods.
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Figure 6. A) Mean number of active nose pokes (timeout); B) mean number of
inactive nose pokes (total); and C) mean number of inactive nose pokes
(timeout) (± SEM) for male and female rats on the last day of behavioral
responding across methamphetamine acquisition training sessions (sucrose
training–session 6). * Indicates a significant difference from male rats (p < .05).
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Post-treatment with nicotine (0.16 mg/kg) altered consumption and
responding for methamphetamine on session 7. Specifically, rats exposed to
saline during the post-treatment period had more active nose pokes within the
reinforcement period, and greater methamphetamine consumption (40 mg/l
methamphetamine solution), than rats exposed to a low dose of nicotine (0.16
mg/kg) during the post-treatment period [post-treatment main effect,
F(1,75) = 4.09, p > .05; F(1,75) = 5.22, p > .05, respectively] (see Figures 7A &
7B). Pre-treatment with nicotine (0.16 mg/kg) did not alter consumption or
responding for methamphetamine on session 7; however, rats exposed to saline
during the pre-treatment period had more total inactive nose pokes compared to
rats exposed to a low dose of nicotine (0.16 mg/kg) during the pre-treatment
period [pre-treatment main effect, F(1,75) = 5.17, p > .05] (see Figures 7E).
Sex also altered responding for methamphetamine on session 7, because
female rats had more total active nose pokes and active nose pokes within the
reinforcement period than male rats [sex main effect, F(1,75) = 4.53, p < .05;
F(1,75) = 5.56, p < .05, respectively] (see Figures 7B, 7C, 8A, & 8B). Female rats
also had more active nose pokes within the timeout period and more total
inactive nose pokes than male rats [sex main effect, F(1,75) = 11.13, p < .01;
F(1,75) = 4.98, p < .05, respectively] (see Figures 7D, 7E, 8C, & 8D).
None of the remaining dependent measures (i.e., inactive nose pokes
during the timeout period) were altered by nicotine (0.16 mg/kg) treatment or sex
(see Figure 7).

72

Active Nose Pokes
(Reinforcement)

Female

10

+
5

200

Female

100
50

80
60
40
20
0

D

Male
Female

20

10

F

Male
Female

10

5

0

SAL-SAL SAL-0.16 0.16-SAL 0.16-0.16

Female

10

Male
Female

Male

20

0

E

B

30

Male

150

0

40

0

C

Active Nose Pokes
(Timeout)

Active Nose Pokes
(Total)

A

15

0

Inactive Nose Pokes
(Total)

50
Male

Inactive Nose Pokes
(Timeout)

Consumption (g)

20

SAL-SAL SAL-0.16 0.16-SAL 0.16-0.16
Treatment Condition

Treatment Condition
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Extinction Training and Drug-Primed Reinstatement
Active nose pokes decreased across the seven extinction days [active,
F(4.04,326.99) = 8.69, p < .001] (see Figure 9A). In contrast, inactive nose pokes
remained relatively constant across extinction days [inactive, F(6,486) = .741,
p = .617] (see Figure 9B).
Total active nose pokes were not altered by nicotine (0.16 mg/kg) pre- or
post-treatment during extinction (see Figure 9A). Rats exposed to saline during
the pre-treatment period had more total inactive nose pokes across extinction
days than rats exposed to nicotine (0.16 mg/kg) during the pre-treatment period
[pre-treatment main effect, F(1,74) = 8.42, p < .01] (see Figure 9B).
Sex altered responding for methamphetamine during extinction.
Specifically, female rats had more total active nose pokes across extinction days
than male rats [sex main effect, F(1,74) = 8.42, p < .01] (see Figures 9A & 9C).
Total inactive nose pokes did not differ by sex during extinction (see Figure 9B).
Total active nose pokes were not altered by nicotine (0.16 mg/kg) pre- or
post-treatment during reinstatement (see Figure 10A). Rats exposed to saline
during the pre-treatment period had more total inactive nose pokes than rats
exposed to a low dose of nicotine (0.16 mg/kg) during the pre-treatment period
[pre-treatment main effect, F(1,75) = 4.43, p < .05] (see Figures 10B & 11).
Lastly, sex did not alter total active and inactive nose pokes during
reinstatement (see Figure 10).
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Figure 9. A) Mean number of active nose pokes (total); B) mean number of
inactive nose pokes (total); and C) mean number of active nose pokes (total)
(± SEM) made by male and female rats during extinction training days 1 – 7.
Rats were exposed to saline (SAL) or nicotine (0.16 mg/kg) during the pretreatment (PD 25–34) or post-treatment (PD 35–~60) phases. * Indicates a
significant difference from male rats (p < .05).
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Effects of Nicotine (0.64 mg/kg) Exposure on Oral Methamphetamine SelfAdministration, Extinction, and Reinstatement
Effect of Nicotine (0.64 mg/kg) Exposure on Bodyweight
Adolescent nicotine (0.64 mg/kg) exposure across the pre- (PD 25−PD 34)
and post-treatment (PD 35−54) phases did not alter bodyweights of either male
or female rats. Bodyweights of all rats progressively increased across the pre(PD 25−PD 34) and post-treatment (PD 35−54) periods [day main effect,
F(1.83,146.32) = 542.52, p > .001] (see Figure 12). Male rats (M = 157.57, SEM
= 2.34) weighed more than female rats (M = 129.47, SEM = 2.36) across the preand post-treatment periods [sex main effect, F(1,73) = 71.64, p > .001] (see
Figure 12).
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Figure 12. Mean body weight (± SEM) of male and female rats exposed to saline
(SAL) or nicotine (0.64 mg/kg) across the pre- (PD 25–34) or post-treatment (PD
35–~60) phases.
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Acquisition of Methamphetamine Self-Administration
Oral methamphetamine self-administration was acquired over six training
sessions, in which sucrose was phased out and methamphetamine was
introduced. On session 7, rats responded for methamphetamine alone. Neither
pre- nor post-treatment with nicotine (0.64 mg/kg) altered consumption or
responding for methamphetamine (see Figure 13). Male rats (M = 7.92, SEM =
.36) consumed more sucrose and methamphetamine than female rats (M = 6.17,
SEM = .37) [sex main effect, F(1,73) = 11.46, p < .01] (see Figure 13A).
None of the remaining dependent measures (i.e., total active and inactive
nose pokes, active and inactive nose pokes during the timeout period) were
altered by nicotine (0.64 mg/kg) or sex (see Figure 14).
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Figure 13. A) Mean sucrose and methamphetamine consumption; and B) mean
number of active nose pokes (reinforcement) (± SEM) made by male and female
rats exposed to saline (SAL) or nicotine (0.64 mg/kg) across the pre- (PD 25–34)
or post-treatment (PD 35–~60) phases during methamphetamine acquisition
training sessions (sucrose training–session 6).
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Figure 14. A) Mean number of active nose pokes (total); B) mean number of
active nose pokes (timeout); C) mean number of inactive nose pokes (total); and
D) mean number of inactive nose pokes (timeout) (± SEM) made by male and
female rats exposed to saline (SAL) or nicotine (0.64 mg/kg) across the pre- (PD
25–34) or post-treatment (PD 35–~60) phases during methamphetamine
acquisition training sessions (sucrose training–session 6).
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Neither pre- nor post-treatment with nicotine (0.64 mg/kg) altered
consumption or responding for methamphetamine on session 7 (see Figure 15).
Sex altered responding for methamphetamine on session 7 because
female rats had more total active nose pokes and more active nose pokes within
the reinforcement period than male rats [sex main effect, F(1,73) = 3.97, p < .05;
F(1,73) = 6.36, p < .05, respectively] (see Figures 15B, 15C, 16A & 16B). Female
rats also had more total inactive nose pokes and more inactive nose pokes within
the timeout period than male rats [sex main effect, F(1,73) = 4.08, p < .05;
F(1,73) = 4.57, p < .05, respectively] (see Figures 15E, 15F, 16C & 16D).
None of the remaining dependent measures (i.e., active nose pokes
during the timeout period) were altered by nicotine (0.64 mg/kg) or sex (see
Figure 15).
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Figure 15. A) Mean methamphetamine (40 mg/l) consumption; B) mean active
nose pokes (reinforcement); C) mean active nose pokes (total); D) mean active
nose pokes (timeout); E) mean inactive nose pokes (total); and F) mean inactive
nose pokes (timeout) (± SEM) made by adolescent male and female rats during
methamphetamine acquisition on session 7 (FR 2). Rats were exposed to saline
(SAL) or nicotine (0.64 mg/kg) during the pre-treatment (PD 25–34) or posttreatment (PD 35–~60) phases.
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Extinction Training and Drug-Primed Reinstatement
Active nose pokes decreased across extinction days [active,
F(2.91,232.4) = 6.73, p < .001] (see Figure 17A). This decrease in active lever
presses was not altered by sex or nicotine (0.64 mg/kg) exposure. Inactive nose
pokes did not significantly change across extinction days [inactive,
F(3.98,318.00) = 1.26, p = .274] (see Figure 17B). Inactive lever presses were
not altered by sex or nicotine (0.64 mg/kg) exposure.
Neither nicotine (0.64 mg/kg) exposure nor sex altered total active or
inactive nose pokes during extinction training (see Figure 17A & 17B). Similarly,
neither nicotine (0.64 mg/kg) exposure nor sex altered total active or inactive
nose pokes during methamphetamine-primed reinstatement (see Figure 18A &
18B).
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Figure 17. A) Mean number of active nose pokes (total); and B) mean number of
inactive nose pokes (total) (± SEM) made by adolescent male and female rats
during methamphetamine extinction. Rats were exposed to saline (SAL) or
nicotine (0.64 mg/kg) during the pre-treatment (PD 25–34) or post-treatment (PD
35–~60) phases.
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inactive nose pokes (total) (± SEM) made by rats during reinstatement. Rats
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CHAPTER ELEVEN
DISCUSSION

Introduction
Cigarette smoking is most likely to begin during the adolescent period, and
often functions as a gateway to other drugs of abuse, such as methamphetamine
(Lewinsohn et al., 1999). Methamphetamine use during adolescence is
particularly troublesome given the severe psychological and physiological
consequences of methamphetamine abuse (Russell et al., 2008; Vearrier et al.,
2012). Given that adolescence is a vulnerable period in development, in which
cigarette smoking can lead to the onset of methamphetamine use and addiction,
it is imperative to investigate the neurobiological relationship between these
highly addictive drugs during the adolescent period (Yuan, Cross, Loughlin, &
Leslie, 2015). Therefore, the aim of the present thesis was to determine the role
of adolescent nicotine exposure on the reinforcing properties of
methamphetamine, as well as drug seeking behavior, through the use of an oral
methamphetamine self-administration procedure.
We had two primary hypotheses. First, we hypothesized that nicotine
exposure would alter methamphetamine self-administration and
methamphetamine drug seeking behavior. Specifically, we predicted that
exposure to a low dose of nicotine (0.16 mg/kg) would enhance the reinforcing
effects of methamphetamine (i.e., increased consumption and more active nose
pokes) compared to rats exposed to saline. Conversely, we predicted that
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exposure to a high dose of nicotine (0.64 mg/kg) would attenuate the reinforcing
effects of methamphetamine (i.e., decreased consumption and a reduced
number of active nose pokes) compared to rats exposed to saline. These
hypotheses were founded in past research showing that exposure to low doses
of nicotine potentiates the rewarding properties of methamphetamine and
cocaine (McQuown et al., 2007; Pipkin et al., 2014), whereas exposure to higher
doses of nicotine attenuates methamphetamine self-administration and
reinstatement (Hiranita et al., 2004; 2006; Neugebauer et al., 2010).
Second, we hypothesized that sex would alter methamphetamine selfadministration and methamphetamine drug seeking behavior. Specifically, we
predicted that female rats would display behavior indicating an enhancement of
the reinforcing effects of methamphetamine (i.e., increased consumption and
more active nose pokes) compared to male rats. These hypotheses were
founded in past research showing that female rats acquire methamphetamine
self-administration more readily (Kucerova, Vrskova, & Sulcova, 2009), as well
as respond more for access to methamphetamine during reinstatement, than
male rats (Ruda-Kucerova et al., 2015).
During methamphetamine acquisition training sessions (i.e., sucrose
training – session 6), nicotine (0.16 or 0.64 mg/kg) exposure did not alter
consumption or responding for methamphetamine; however, rats exposed to
saline had more inactive nose pokes within the timeout period than rats exposed
to a low dose of nicotine (0.16 mg/kg).
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During methamphetamine self-administration (i.e., session 7), nicotine
(0.16 mg/kg) exposure altered consumption and responding for
methamphetamine. In contrast to our hypotheses, rats exposed to saline during
the post-treatment period had more active nose pokes during the reinforcement
period and more methamphetamine consumption than rats exposed to a low
dose of nicotine (0.16 mg/kg) during the post-treatment period. Nicotine (0.16
mg/kg) exposure during the pre-treatment period did not alter consumption or
responding for methamphetamine. Rats exposed to saline during the pretreatment period had more total inactive nose pokes compared to rats exposed to
a low dose of nicotine (0.16 mg/kg) during the pre-treatment period. Neither prenor post-treatment with a high dose of nicotine (0.64 mg/kg) altered consumption
or responding for methamphetamine during self-administration.
During the extinction and reinstatement periods, nicotine (0.16 or 0.64
mg/kg) exposure did not alter consumption or responding for methamphetamine;
however, rats exposed to saline during the pre-treatment period had more total
inactive nose pokes across extinction days than rats exposed to nicotine (0.16
mg/kg) during the pre-treatment period. During the reinstatement period, rats
exposed to saline during the pre-treatment period had more total inactive nose
pokes than rats exposed to a low dose of nicotine (0.16 mg/kg) during the pretreatment period.
The present results also demonstrated that oral methamphetamine selfadministration differed by sex. Consistent with our hypotheses, female rats had
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augmented total active nose pokes and a greater number of active nose pokes
within the reinforcement period compared to male rats. Conversely, male rats
showed augmented sucrose and methamphetamine solution consumption across
methamphetamine acquisition training sessions (i.e., sucrose training – session
6). Female rats had augmented total inactive nose pokes, as well as more active
and inactive nose pokes, within the timeout period compared to male rats. During
extinction, female rats had an augmented number of total inactive nose pokes
compared to male rats; however, no sex differences were observed during
methamphetamine reinstatement.
From a methodological perspective, the present thesis highlights that oral
methamphetamine self-administration can be achieved in adolescent rats.
Specifically, all groups, regardless of sex or drug treatment, exhibited
consumption and operant responding for methamphetamine through the oral
route of administration. To our knowledge, very few studies have utilized oral
methamphetamine self-administration in mice (Shabani et al., 2013), with no
published research demonstrating this effect in rats. As a genetic animal model
of methamphetamine addiction, Shabani et al. (2013) utilized selectively bred
mice to consume methamphetamine at either high or low rates. These
researchers found that high methamphetamine-drinking mice have augmented
intake, but a similar number of active lever presses when compared to low
methamphetamine-drinking mice in the oral self-administration procedure. In
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addition, they found comparable results utilizing an intracerebroventricular route
of methamphetamine self-administration.
The present thesis and Shabani et al. (2013) utilized similar acquisition
training, in which sucrose faded-out and methamphetamine faded-in across
seven different sessions. This type of acquisition is frequently used in oral
ethanol self-administration studies (Ford et al., 2009). One difference between
acquisition in the present thesis and Shabani et al. (2013) includes the use of
sucrose or saccharin, respectively. In addition, mice in Shabani et al. (2013)
underwent five, 1 hr operant trials for every change in solution or fixed ratio
scheduling, resulting in a total of 35 operant trials. In the present thesis, rats
underwent 2 hr operant trials, in which advancement to the next session was
dependent on meeting specific criteria (e.g., 10 or more presentations). Due to
the short adolescent period in rats (~30 days), it was necessary to utilize the
more abbreviated acquisition schedule to allow additional time for nicotine pretreatment (i.e., 10 days). It is unclear whether these methodological differences
affect the acquisition of oral methamphetamine self-administration; however,
Shabani et al., 2013 suggest that increasing the number of operant trials per
session facilitates the stabilization of behavior associated with each solution type.
Taken together, findings from the present thesis and past research
demonstrate that oral methamphetamine self-administration is attainable in both
rats and mice. It is important to determine whether this effect in rats is agespecific. Future research may consider testing oral methamphetamine self-
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administration in adult rats, as evidence suggests that drugs of abuse, such as
methamphetamine, have a heightened reward value in adolescent rats, and this
age group has a diminished sensitivity for the aversive effects of the drug
(Schramm-Sapyta, Morris, & Kuhn, 2006; Schramm-Sapyta et al., 2009).
The present data supports previous findings that nicotine exposure
attenuates behavioral responding for methamphetamine during selfadministration and reinstatement (Hiranita et al., 2004; 2006; Neugebauer et al.,
2010). Specifically, adolescent male and female rats exposed to a low dose of
nicotine (0.16 mg/kg) during the post-treatment (PD 35–~60) period had
attenuated active nose pokes and reduced methamphetamine consumption
across methamphetamine (40 mg/l) self-administration. Similarly, adolescent
male and female rats exposed to a low dose of nicotine (0.16 mg/kg) during the
pre-treatment (PD 25–34) period had attenuated total inactive nose pokes during
the methamphetamine (40 mg/l) self-administration, extinction, and reinstatement
phases. Neugebauer et al. (2010) found that adult male rats exposed to a higher
dose of nicotine (0.40 mg/kg) showed a reduction in responding for
methamphetamine access during self-administration, while a lower dose of
nicotine (0.20 mg/kg) had no effect. This nicotine-induced attenuation of
responding for methamphetamine was only observed at a higher fixed ratio
schedule (i.e., FR 5) and was not observed at lower fixed ratio scheduling (i.e.,
FR 1) (Neugebauer et al., 2010). The authors attribute this finding to the
susceptibility of nicotine to disrupt higher, but not lower rates of responding;

95

however, data from the present thesis suggests that a low dose of nicotine can
also attenuate responding for methamphetamine at low rates of responding (i.e.,
FR 2).
The present findings also show that nicotine exposure reduces responding
for methamphetamine access during extinction and methamphetamine-primed
reinstatement. Hiranita et al. (2004) found that adult male rats showed a
reduction in methamphetamine seeking behavior during primed reinstatement
following a repeated or single nicotine (0.30 mg/kg) exposure during a
methamphetamine-withdrawal period. In addition, the nicotine-induced
attenuation of methamphetamine seeking behavior was blocked by exposure to
the nicotinic antagonist mecamylamine, thus demonstrating that the cholinergic
system may be important in methamphetamine relapse (Hiranita et al., 2004;
2006). Hiranita et al. (2006) found the attenuating effects of nicotine on
methamphetamine seeking behavior was not altered by the muscarinic
antagonist scopolamine, indicating that the inactivation of nicotinic ACh receptors
is important for methamphetamine seeking behavior.
Despite the clear methodological differences, the present findings and
Hiranita et al. (2004; 2006) demonstrate a relationship between the nicotinic ACh
system and methamphetamine seeking behavior. Within the CNS, the α4β2 and
α7 nAChRs are the main receptor subtypes, with each receptor thought to play a
different role in drug-seeking behavior (Grottick, Wyler, & Higgins, 2000).
Compared to adults, adolescent α4β2 and α7 nAChRs expression and binding are
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augmented in many different brain areas (Yuan et al., 2015). When exposed to
the selective α4β2 nAChR antagonist DhβE in the nucleus accumbens core and
prelimbic cortex, the AM251-induced (i.e., cannabinoid receptor 1 antagonist)
attenuation of methamphetamine seeking behavior is blocked (Hiranita et al.,
2008). However, exposure to the selective α7 nAChR antagonist MLA does not
alter the AM251-induced attenuation of methamphetamine seeking behavior,
suggesting that normal functioning of the α4β2 nAChR plays an important role in
methamphetamine seeking behavior (Hiranita et al., 2008). In addition, nicotine
and ACh have a greater affinity for the α4β2 nAChR compared to α7, further
indicating the importance of the α4β2 nAChR (Decker, Brioni, Bannon, & Arneric,
1995; Gotti, Zoli, & Clementi, 2006). Taken together, it is possible that the
nicotine-induced attenuation of methamphetamine seeking behavior observed in
the present thesis may be due, in part, to the activation of the α4β2 nAChR.
The present findings contrast with previous work showing that daily
nicotine (0.16 mg/kg) treatment beginning in adolescence increases
methamphetamine infusions, as well as active, inactive, and timeout lever
presses in adult male rats (Pipkin et al., 2014). A potential explanation for the
differing results is the self-administration procedures being used. Specifically,
Pipkin et al. (2014) utilized intravenous self-administration of methamphetamine
and found that nicotine exposure augmented responding for methamphetamine,
whereas the present study used an oral method of methamphetamine selfadministration. The oral self-administration procedures used in the present study
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were adopted from oral ethanol self-administration studies, wherein the drug is
introduced in a sweetened solution and faded out across acquisition training
(Ford et al., 2009). The drug is orally consumed and must first pass through the
gastrointestinal lining and subsequently enters the blood stream. In contrast, the
intravenous self-administration method requires surgery and the insertion of a
catheter into the jugular vein, wherein the drug is directly infused into the
bloodstream. Despite the disadvantages of oral self-administration procedures
(e.g., delay in onset of the psychoactive effects of methamphetamine or the
degradation of the drug via digestive enzymes and alternating pH levels), it is
apparent that our rats did readily oral self-administer methamphetamine in the
present thesis. It is not clear as to the extent this methodological difference
played a role in the differing results found in the present thesis and Pipkin et al.
(2014), but future direct comparisons of the two methamphetamine selfadministration procedures are warranted and may provide further clarity on this
issue.
Another explanation for the inconsistent results found in the present study
and results from Pipkin et al. (2014) may be due to the age that rats were
exposed to nicotine and tested on the methamphetamine self-administration
procedures. Maturational changes in ACh and related neurotransmitter systems
occur across early ontogeny and into adulthood (Yuan et al., 2015). For example,
nAChR stimulation causes augmented ventral striatal DA release during
adolescence when compared to adulthood (Azam et al., 2007). Nicotine
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exposure leads to an increase of DA release via the mesolimbic reward pathway,
in which consistently heightened DA levels results in the desensitization of these
neurons (Pidoplichko, DeBiasi, Williams, & Dani, 1997). In addition,
methamphetamine exposure leads to heightened DA release in the mesolimbic
reward pathway (Dobbs & Mark, 2012). Age-related effects of nicotine exposure
may be due, in part, to the protective mechanisms of nicotine against
methamphetamine-induced dopaminergic deficits (Vieira-Brock et al., 2015).
Stimulation of the α4β2 nAChR via nicotine exposure may act as a
neuroprotective mechanism against methamphetamine-induced DA deficits
(Baladi, Nielsen, McIntosh, Hanson, & Fleckenstein, 2016; Vieira-Brock et al.,
2015). Specifically, adolescent nicotine exposure (PD 41−61) attenuates
methamphetamine-induced striatal dopaminergic deficits through α4β2 nAChR
stimulation; however, this nicotine-induced neuroprotection was more
pronounced in rats chronically treated with nicotine beginning in adolescence and
ending in adulthood (Vieira-Brock et al., 2015). In contrast, nicotine exposure
beginning in adulthood did not result in the same neuroprotection as adolescent
nicotine administration, suggesting that the neuroprotective effects of nicotine
against methamphetamine-induced DA deficits are age-related (Vieira-Brock et
al., 2015). Taken together, these findings and data from the present thesis
support the notion that nicotine exposure during the adolescent period acts to
protect against methamphetamine-induced DA deficits and decreases the robust
reinforcing properties of methamphetamine (Vieira-Brock et al., 2015). Moreover,
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the nicotine-induced attenuation of responding for methamphetamine during selfadministration may be due to the age-related differences in the neuroprotective
effects of α4β2 nAChR stimulation. Future research should consider investigating
the specific neural mechanisms surrounding the nicotine-induced attenuation of
responding for methamphetamine in adolescent rats.
In the present thesis, female rats consistently responded for access to
methamphetamine more than male rats during self-administration. Clinical
reports show that females account for approximately 50% of adolescent
methamphetamine users (Chen et al., 2014). Females report methamphetamine
initiation at a younger age, a greater psychological burden and severity of
methamphetamine use, and a more rapid increase in the frequency of
methamphetamine use when compared to male users (Dluzen & Liu, 2008; Liu,
Wang, Chu, & Chen, 2013; Rawson, Gonzales, Obert, McCann, & Brethen,
2005; Simpson et al., 2016). Men show a significant correlation between
methamphetamine cravings and depression or anxiety while females do not
show the same correlation, thus indicating that females do not share some of the
same side effects from methamphetamine use as men (Hartwell, Moallem,
Courtney, Glasner-Edwards, & Ray, 2016). Similar to clinical reports, pre-clinical
findings indicate that female rats acquire methamphetamine self-administration
more rapidly and exhibit a more robust reinstatement than male rats (Kucerova,
et al., 2009; Reichel et al., 2012; Roth & Carroll, 2004; Ruda-Kucerova et al.,
2015). Thus, the present data support and extend previous clinical and pre-
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clinical findings, in which female rats consistently respond more for access to
methamphetamine than male rats during an oral self-administration procedure.
In contrast to data from adolescent rats exposed to a low dose of nicotine
(0.16 mg/kg), data from adolescent rats exposed to a high dose of nicotine (0.64
mg/kg) suggests that nicotine exposure does not alter responding for access to
methamphetamine during adolescence. The reason for this dose-dependent
effect is unknown; however, higher doses of nicotine (e.g., > 0.60 mg/kg) can be
averse (Torres et al., 2008). Given that a low dose of nicotine (0.16 mg/kg) in the
present thesis altered responding for methamphetamine and a high dose of
nicotine (0.64 mg/kg) did not, the aforementioned explanation is unlikely.
Previous preclinical work is mixed in regard to the disruption of
methamphetamine self-administration by a high dose of nicotine. Specifically,
Neugebauer et al. (2010) found a reduction in responding for methamphetamine
following exposure to a higher dose of nicotine (0.40 mg/kg), while a lower dose
of nicotine (0.20 mg/kg) had no effect. Consistent with the present thesis, Pipkin
et al. (2014) found that a high dose of nicotine (0.64 mg/kg) did not alter
responding for methamphetamine. Pipkin et al. (2014) suggest these findings
maybe due to response competition (i.e., high nicotine doses induce stereotyped
behavior that interferes with responding for methamphetamine). Again, this
explanation is also unlikely, as we found that a low dose of nicotine, but not a
high dose, attenuated responding for methamphetamine.
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Interestingly, we consistently found that inactive nose pokes were
attenuated in rats treated with a low dose of nicotine (0.16 mg/kg) across
methamphetamine self-administration, extinction, and reinstatement. This finding
suggests that nicotine exposure reduced activity and impulsivity levels of rats
during these periods. Prior clinical research suggests that impulsivity and drug
dependence are positively correlated, with impulsivity being a strong predictor of
nicotine and methamphetamine dependence (Balevich, Wein, & Flory, 2013;
Ryan, MacKillop, & Carpenter, 2013; Tziortzis, Mahoney, Kalechstein, Newton, &
De La Garza, 2011). Impulsivity also enhances an individual’s vulnerability to
relapse (Kreek, Nielsen, Butelman, & LaForge, 2005). Therefore, the present
study contrasts with previous clinical work and suggests that exposure to a low
dose of nicotine (0.16 mg/kg) reduces impulsivity of rats during
methamphetamine self-administration, extinction, and reinstatement.
In addition, we found that female rats had heightened inactive nose pokes
compared to male rats during methamphetamine self-administration and
extinction. This finding suggests that female rats exposed to methamphetamine
were more active and impulsive than similarly treated male rats. Previous clinical
work suggests there are no sex differences in the impulsivity of
methamphetamine users (Kogachi, Chang, Alicata, Cunningham, & Ernst, 2017).
However, sex differences in methamphetamine users may be a function of age,
as younger female methamphetamine users tend to have higher impulsivity
scores (Kogachi et al., 2017; Semple, Zians, Grant, & Patterson, 2005).
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Preclinical research suggests that sex differences in activity and impulsivity
levels also occur in methamphetamine-treated rats. Consistent with the present
study, female rats exposed to methamphetamine had more inactive lever
presses than similarly-treated male rats (Reichel et al., 2012).
The present results suggest that adolescents are exceedingly sensitive to
nicotine doses. Adolescents who undergo treatment for methamphetamine
addiction may benefit from the nueroprotective effects of exposure to a low dose
of nicotine, while exposure to higher doses of nicotine may be counter
productive. Thus, for adolescents who already present cigarette smoking
behavior at the time of methamphetamine addiction treatment, total abstinence
from both nicotine and methamphetamine may be a less effective form of
treatment. It may be clinically beneficial to first treat the methamphetamine
addiction, and subsequently treat the nicotine addiction. Regardless of the
method of treatment for adolescent methamphetamine addiction, nicotine
exposure should be closely monitored.
Taken together, data resulting from exposure to a low dose of nicotine
(0.16 mg/kg) and a high dose of nicotine (0.64 mg/kg) differentially supports the
gateway theory of drug addiction, which suggests that using legal drugs, such as
nicotine, increases the propensity for subsequent use of illicit drugs, such as
methamphetamine (Lewinsohn et al., 1999). Within a strictly social context, it is
likely that nicotine use may indeed lead to subsequent methamphetamine use,
as approximately 97% of methamphetamine users also smoke cigarettes (Brecht
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et al., 2004). From a purely pharmacological perspective, it is also apparent that
moderate adolescent nicotine exposure can be protective against the robust
reinforcing properties of methamphetamine; whereas, heightened adolescent
nicotine exposure does not alter the reinforcing properties of methamphetamine.

Conclusion
The major findings from the present thesis are threefold: a) oral
methamphetamine self-administration, extinction, and reinstatement are
attainable in adolescent rats; b) exposure to a low dose of nicotine (0.16 mg/kg)
attenuates the reinforcing properties of methamphetamine; c) exposure to a high
dose of nicotine (0.64 mg/kg) does not alter the reinforcing properties of
methamphetamine. The present research extends previous results showing: 1)
oral methamphetamine self-administration is possible in mice (Shabani et al.,
2013); 2) exposure to nicotine has neuroprotective effects, resulting in the
attenuation of methamphetamine seeking during methamphetamine selfadministration, extinction, and primed reinstatement (Baladi et al., 2016; Hiranita
et al., 2004; 2006; Neugebauer et al., 2010; Vieira-Brock et al., 2015); and 3)
exposure to a high dose of nicotine does not alter acquisition of
methamphetamine self-administration (Pipkin et al., 2014).
Future research may consider investigating oral methamphetamine selfadministration in adult rats, as adolescent rats exhibit heightened reward and
diminished sensitivity to the aversive effects of drugs of abuse, such as
methamphetamine (Schramm-Sapyta et al., 2006, 2009). Future research should
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also consider investigating the specific neural mechanisms surrounding the
nicotine-induced attenuation of responding for methamphetamine during selfadministration, extinction, and reinstatement in adolescent rats.
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